DK174386B1 - Bicyclic imino-alpha-carboxylic acid esters, process for their preparation by separating racemic mixtures thereof, optionally in the form of their hydrochloride or tosylate salt, and diastereomeric salt in the form of a protected N-acylated, ...... - Google Patents

Bicyclic imino-alpha-carboxylic acid esters, process for their preparation by separating racemic mixtures thereof, optionally in the form of their hydrochloride or tosylate salt, and diastereomeric salt in the form of a protected N-acylated, ...... Download PDF

Info

Publication number
DK174386B1
DK174386B1 DK198400415A DK41584A DK174386B1 DK 174386 B1 DK174386 B1 DK 174386B1 DK 198400415 A DK198400415 A DK 198400415A DK 41584 A DK41584 A DK 41584A DK 174386 B1 DK174386 B1 DK 174386B1
Authority
DK
Denmark
Prior art keywords
formula
atoms
carboxylic acid
chain
optionally
Prior art date
Application number
DK198400415A
Other languages
Danish (da)
Other versions
DK41584A (en
DK41584D0 (en
Inventor
Volker Teetz
Hansjoerg Urbach
Rainer Henning
Rolf Geiger
Dietrich Langner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19833303139 external-priority patent/DE3303139A1/en
Priority claimed from DE19833303112 external-priority patent/DE3303112A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of DK41584D0 publication Critical patent/DK41584D0/en
Publication of DK41584A publication Critical patent/DK41584A/en
Application granted granted Critical
Publication of DK174386B1 publication Critical patent/DK174386B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54Spiro-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

i DK 174386 B1in DK 174386 B1

Opfindelsen angår en fremgangsmåde til adskillelse af racemiske blandinger af bicycliske imino-a-carboxylsyre-estere i komponenterne med formlen la og Ib 5 p2 2 T ? C B2 B A—/ coon KOOC \-/B<The invention relates to a process for separating racemic mixtures of bicyclic imino-α-carboxylic acid esters into the components of formula Ia and Ib 5 p2 2 T? C B2 B A— / coon KOOC \ - / B <

10 A 7 ”"H10 A 7 "" H

Η HΗ H

(Ib) 15 hvor substituenterne har de nedenfor angivne betydninger eller det tilsvarende hydrochlorid- eller tosylatsalt.(Ib) 15 wherein the substituents have the meanings given below or the corresponding hydrochloride or tosylate salt.

Racematadskillelsen af aminosyrer via krystallisation af diastereoisomere salte er en meget benyttet fremgangsmåde (oversigt: Boyle, Quart, Rev., 25 (1971) 323). For det meste 2 0 anvendes N-acylerede aminosyrer,* saltene krystalliseres med alkaloidbaser, og de ensartede diastereoisomere salte adskilles, f.eks. ved ekstraktion af N-acylaminosyrerne fra opløsningen, som er gjort sur (J. Amer. Chem. Soc., 71 (1949) 2541, 3251). Man kan også gå frem på omvendt måde 25 og krystallisere aminosyreestere eller -amider med optisk aktive syrer (Chem. Ber., 8j> (1953) 1524).The racemate separation of amino acids via crystallization of diastereoisomeric salts is a widely used method (overview: Boyle, Quart, Rev., 25 (1971) 323). Mostly 20 N-acylated amino acids are used, the salts are crystallized with alkaloid bases, and the uniform diastereoisomeric salts are separated, e.g. by extracting the N-acylamino acids from the acidic acid solution (J. Amer. Chem. Soc., 71 (1949) 2541, 3251). Alternatively, one can proceed in reverse manner and crystallize amino acid esters or amides with optically active acids (Chem. Ber., 8j> (1953) 1524).

Hertil anvender man eksempelvis optisk aktive forbindelser, f.eks. 10-camphersulfonsyre, abietinsyre eller vinsyre eller disses O-derivater. Denne fremgangsmåde 30 er frem for alt hensigtsmæssig, når optisk aktive aminosyreestere skal anvendes som udgangsforbindelser til videre synteser. I dette tilfælde er det ufordelagtigt først at fremstille en N-acylforbindelse, derpå at foretage racematadskillelsen via saltdannelse med optisk aktive 35 baser, at spalte acylgruppen fra og derpå at forestre den frie aminosyre.For example, optically active compounds, e.g. 10-camphorsulfonic acid, abietic acid or tartaric acid or their O-derivatives. This method 30 is particularly useful when optically active amino acid esters are to be used as starting compounds for further synthesis. In this case, it is disadvantageous to first prepare an N-acyl compound, then to make the racemate separation via salt formation with optically active bases, to cleave the acyl group and then esterify the free amino acid.

2 DK 174386 B12 DK 174386 B1

Der er hidtil ikke beskrevet en egnet fremgangsmåde til adskillelse af racemiske blandinger af bicycliske amino-α-carboxylsyreestere. Den eksperimentelle undersøgelse har vist, at alle gængse syrer er uegnede til racematadskillel-5 sen. Til octahydroindol-2-carboxylsyre kendes der fra EP patentansøgning nr. 37.231 en fremgangsmåde, ifølge hvilken racematets N-benzoylforbindelse kan adskilles via saltet med optisk aktivt a-phenylethylamin. Af de nævnte årsager er denne fremgangsmåde imidlertid uøkonomisk, når esterne 10 er nødvendige som mellemprodukt til videre synteser.So far, no suitable method has been described for separating racemic mixtures of bicyclic amino-α-carboxylic acid esters. The experimental study has shown that all common acids are unsuitable for the racial separation. For octahydroindole-2-carboxylic acid, there is known from EP Patent Application No. 37,231 a process according to which the N-benzoyl compound of the racemate can be separated via the salt with optically active α-phenylethylamine. However, for the reasons mentioned, this process is uneconomical when the esters 10 are needed as intermediates for further synthesis.

Det har nu overraskende vist sig, at N-acyl-derivater af optisk aktive R- eller S-aminosyrer, som indeholder en phenylkerne, f.eks. S-phenylalanin, tyrosin eller tyrosin-0-derivater, er egnede som chirale partnere for de bicycliske 15 imino-a-carboxylsyreestere. Derved udfældes fra egnede opløsningsmidler for det meste (S,S)- eller (R,R)-saltene spontant, mens (S,R)- og (R,S) saltene forbliver i opløsningen. Allerede i ét skridt kan der opnås en mere end 95%'s berigelse, og en enkelt omkrystallisation giver i højt ud-20 bytte de optisk ensartede salte, som på kendt måde kan adskilles .It has now surprisingly been found that N-acyl derivatives of optically active R or S amino acids containing a phenyl core, e.g. S-phenylalanine, tyrosine or tyrosine-O derivatives, are suitable as chiral partners for the bicyclic imino-α-carboxylic acid esters. Thereby, from suitable solvents, most of the (S, S) or (R, R) salts are precipitated spontaneously, while the (S, R) and (R, S) salts remain in the solution. Already in one step, an enrichment of more than 95% can be obtained, and a single recrystallization gives in high yield the optically uniform salts which can be separated in a known manner.

Opfindelsen angår følgelig en fremgangsmåde til adskillelse af racemiske blandinger af bicycliske imino-a-carboxylsyreestere i komponenterne med formlerne la og Ib 25 B2 C C B2 B —/ cooa rooc \—L B 1 35Accordingly, the invention relates to a process for separating racemic mixtures of bicyclic imino-α-carboxylic acid esters into the components of formulas Ia and Ib 25 B2 C C B2 B - / cooa rooc

HH

(la) (Ib) 3 DK 174386 B1 i hvilke R står for en aliphatisk gruppe med 1-6 C-atomer, en alicyclisk gruppe med 4-10 C-atomer, en aromatisk gruppe med 6-12 C-atomer, eller 5 en araliphatisk gruppe med 7-15 C-atomer, som eventuelt kan være substitueret med NC>2, a) A og B1 betyder hydrogen, og 2 B og C danner tilsammen en kæde med formlen ”(CH2^n~ med n = 3, 4, 5 eller 6 eller en kæde med 10 formlen -(CH2)p-CH=CH-(CH2)g- med (p+q) =1, 2, 3 eller 4, eller 2 b) C og B betyder hydrogen, og A og B1 danner tilsammen en kæde med formlen “(CH2^n“ med n = 3, 4, 5 eller 6 eller en kæde med formlen 15 -(CH,) -CH=CH-(CH,) - med (p+q) = 1, 2, 3 eller 4, eller c) A og C betyder hydrogen, og 1 2 B og B danner tilsammen en kæde med formlen -(CH2)m-med m = 4, 5, 6 eller 7, 20 eller det tilsvarende hydrochlorid- eller tosylatsalt, ved krystallisation af diastereomere salte, hvilken fremgangsmåde er ejendommelig ved, at man til en racemisk blanding af forbindelser med formel la eller Ib sætter en N-acyleret, optisk aktiv R- eller S-aminocarboxylsyre, som 25 indeholder en phenylkerne, og hvis aminofunktion og eventuelt tilstedeværende, frie hydroxyfunktioner eventuelt er beskyttet, hvorefter de dannede salte omkrystalliseres fra et aprotisk organisk opløsningsmiddel eller en alkohol med op til 6 C-atomer, de udfældede, optisk ensartede diastereomere 30 salte adskilles på i og for sig kendt måde, og enantiomerene med formlen la eller Ib isoleres, eventuelt i form af deres hydrochlorid- eller tosylatsalt.(1a) (Ib) 3 wherein R represents an aliphatic group of 1-6 C atoms, an alicyclic group of 4-10 C atoms, an aromatic group of 6-12 C atoms, or 5 an araliphatic group having 7-15 C atoms which may be optionally substituted with NC> 2, a) A and B1 represent hydrogen and 2 B and C together form a chain of formula "(CH2 ^ n ~ with n = 3 , 4, 5 or 6 or a chain of formula - (CH2) p -CH = CH- (CH2) g- with (p + q) = 1, 2, 3 or 4, or 2 b) C and B means hydrogen and A and B1 together form a chain of formula "(CH 2 n" with n = 3, 4, 5 or 6 or a chain of formula 15 - (CH 2) -CH = CH- (CH 2) - with (p + q) = 1, 2, 3 or 4, or c) A and C represent hydrogen and 1 2 B and B together form a chain of formula - (CH 2) m-with m = 4, 5, 6 or 7, 20 or the corresponding hydrochloride or tosylate salt, by crystallization of diastereomeric salts, which is characterized by adding to a racemic mixture of compounds of formula Ia or Ib is an N-acylated, optically active R or S-aminocarboxylic acid containing a phenyl nucleus and whose amino function and optionally free hydroxy functions are optionally protected and the salts formed are recrystallized from an aprotic organic solvent or an alcohol of up to 6 C atoms, the precipitated, optically uniform diastereomeric 30 salts are separated in a manner known per se and the enantiomers of formula Ia or Ib are isolated, optionally in the form of their hydrochloride or tosylate salt.

Foretrukken er racematadskillelsen af forbindelser med formlen la eller Ib, hvor 35 a) A og B1 betyder hydrogen, og og C danner tilsammen en kæde med formlen 4 DK 174386 B1 (0¾) n“ n = 3, 4, 5 eller 6 eller en kæde med formlen - (CH2) p-CH=CH-(CH2) q- med (p+q) = 1, 2, 3 eller 4, eller b) C og B2 betyder hydrogen, og 5 A og B1 danner tilsammen en af ovenstående under a) definerede kæder.Preferred is the racial separation of compounds of formula Ia or Ib, wherein a) A and B1 are hydrogen, and and C together form a chain of formula 4 n = n, 3, 4, 5 or 6 or a chain of formula - (CH2) p -CH = CH- (CH2) q- with (p + q) = 1, 2, 3 or 4, or b) C and B2 represent hydrogen and 5A and B1 together form a of the above defined under (a) chains.

En særlig foretrukken fremgangsmådevariant er ejendommelig ved, at man udskiller saltene af racemiske, bi-cycliske estere med formlerne la og Ib, i hvilke de to bro-10 hoved-hydrogenatomer er i cis-konfiguration, og COOR-gruppen er i endo-stilling i forhold til det bicycliske ringsystem, på krystallinsk form.A particularly preferred process variant is the separation of the salts of racemic, bicyclic esters of formulas Ia and Ib, in which the two bridging main hydrogen atoms are in cis configuration and the COOR group is in the endo position. relative to the bicyclic ring system, in crystalline form.

På tale som imino-a-carboxylsyreestere kommer først og fremmest hydrogenolytisk eller hydrolytisk spaltelige 15 estere med aliphatiske, alicycliske eller araliphatiske alkoholer, som de f.eks. er beskrevet i Houben-Weyl, Methoden der organischen Chemie, Bd. XV/1, Stuttgart 1974, s. 314-427, eller af Bodanszky et al. I "Peptide Synthesis", 2. oplag (1976), John Wiley & Sons. Foretrukne er estere med formlen 20 la + Ib, i hvilke R står for alkyl med 1-6 C-atomer, cyclo-alkyl med 4-8 C-atomer eller aralkyl med 7-13 C-atomer, som eventuelt kan være substitueret med N02, især alkylestere med op til 4 alkyl-C-atomer, og aralkylestere, f.eks. benzyl-, nitrobenzyl- eller benzhydrylestere.Speaking as imino-α-carboxylic acid esters, first of all, hydrogenolytic or hydrolytically cleavable esters come with aliphatic, alicyclic or araliphatic alcohols, such as those of e.g. is described in Houben-Weyl, The Method of Organic Chemistry, Vol. XV / 1, Stuttgart 1974, pp. 314-427, or by Bodanszky et al. In "Peptide Synthesis", 2nd edition (1976), John Wiley & Sons. Preferred are esters of formula 20a + 1b in which R stands for alkyl of 1-6 C atoms, cycloalkyl of 4-8 C atoms or aralkyl of 7-13 C atoms, which may be optionally substituted by NO2, especially alkyl esters having up to 4 alkyl C atoms, and aralkyl esters, e.g. benzyl, nitrobenzyl or benzhydryl esters.

25 På tale som N-acylerede aminocarboxylsyrer, som indeholder en phenylkerne, kommer eksempelvis derivater af R-eller S-phenylalanin, -C-phenylglycin, -β-phenyl-a-amino--smørsyre, -3,4-dihydroxyphenyialanin, -β-phenylserin og -tyrosin. Foretrukne er N-acyl-derivater af R- eller 30 S-phenylalanin, -C-phenylglycin og -tyrosin.Speaking as N-acylated aminocarboxylic acids containing a phenyl core, for example, derivatives of R- or S-phenylalanine, -C-phenylglycine, -β-phenyl-α-amino-butyric acid, -3,4-dihydroxyphenylalanine, - β-phenylserine and tyrosine. Preferred are N-acyl derivatives of R- or S-phenylalanine, -C-phenylglycine and tyrosine.

Anvendelige som N-acyl-beskyttelsesgrupper er f.eks. de i Houben-Weyl, Bd. XV/1, side 46-305, eller i Bodanszky et al., "Peptide Synthesis", 2. oplag (1976),Useful as N-acyl protecting groups are e.g. those in Houben-Weyl, Bd. XV / 1, pages 46-305, or in Bodanszky et al., "Peptide Synthesis", 2nd Edition (1976),

John Wiley & Sons,beskrevne gængse NH^-beskyttelses-35 grupper. Foretrukne er alkanoyl med 1-6 C-atomer, især formyl, tert.butoxycarbonyl og benzyloxycarbonyl.John Wiley & Sons, described common NH 2 protecting groups. Preferred are alkanoyl having 1-6 C atoms, especially formyl, tert-butoxycarbonyl and benzyloxycarbonyl.

5 DK 174386 B15 DK 174386 B1

Eventuelt tilstedeværende frie OH-grupper kan eventuelt være O-alkylerede med alkyl med 1-6 C-atomer, især methyl, ethyl eller tert.butyl, med benzyl eller andre i peptid-kemien gængse OH-beskyttelsesgrupper (jfr. f.eks. Houben-5 -Weyl, Bd. XV/1, eller Bodanszky et al., "Peptide Synthesis", 2. oplag (1976), John Wiley & Sons),Optionally, free OH groups present may optionally be O-alkylated with alkyl of 1-6 C atoms, in particular methyl, ethyl or tert-butyl, with benzyl or other OH-protecting groups common in the peptide chemistry (cf. e.g. Houben-5-Weyl, Vol. XV / 1, or Bodanszky et al., "Peptide Synthesis", 2nd Edition (1976), John Wiley & Sons),

Som opløsningsmidler anvendes fortrinvis aprotiske, organiske opløsningsmidler såsom estere, ethylacetat, cyclo-hexan og tetrahydrofuran, men også alkoholer med op til 6 10 C-atomer kan anvendes.As solvents, aprotic organic solvents such as esters, ethyl acetate, cyclohexane and tetrahydrofuran are preferably used, but also alcohols with up to 610 C atoms can be used.

Octahydroindol-2-carboxylsyre er kendt fra US-patentskrift nr.4.350.704. DE-offentliggørelsesskrift nr. 32 26 768 omhandler 2-azabicyclo(3,3,0]octan-3-carboxylsyre, og 2,3,3a,4,5,7a-hexahydro[IH]rndol-2-carboxylsyre er gen-15 stand for DE-offentliggørelsesskrift nr. 32 10 496, ligesom octahydroisoindol-1-carboxylsyre samt 3-azabicyclo[3,3,0]oc-tan-4-carboxylsyre er genstand for DE-offentliggørelses-skrift nr. 32 11 676.Octahydroindole-2-carboxylic acid is known from U.S. Patent No. 4,350,704. DE-A-32 26 768 discloses 2-azabicyclo (3,3,0] octane-3-carboxylic acid, and 2,3,3a, 4,5,7a-hexahydro [1 H] -indole-2-carboxylic acid are 15 publication DE 32,109,66, and octahydroisoindole-1-carboxylic acid and 3-azabicyclo [3,3,0] oc-tan-4-carboxylic acid are the subject of DE-publication no. 3211676.

Racemiske bicycliske cis,endo-imino-a-carboxylsyrer 20 med formlen la + Ib, i hvilke C og B2 betyder hydrogen, og A og B1 tilsammen betyder den ovenfor under b) nævnte kæde, kan eksempelvis fremstilles ud fra enaminer af en cycloal-kanon, som omsættes med N-acylerede S-halogen-or-amino-carb-oxylsyreestere med formlen IV, 25 X’ \ ch2 I (IV)Racemic bicyclic cis, endo-imino-α-carboxylic acids 20 of formula Ia + Ib, in which C and B2 represent hydrogen and A and B1 together represent the chain mentioned above under b), can be prepared, for example, from enamines of a cycloalic acid. canon which is reacted with N-acylated S-halo-or-amino-carboxylic acid esters of formula IV, 25 X

^ CH^ CH

30 Y’-HtJ XC00R4 hvor X' står for en nucleofug gruppe, fortrinsvis chlor eller brom, Y1 står for alkanoyl med 1-5 C-atomer, aroyl med 7-9 C-atomer eller andre i peptidkemien gængse, surt fraspaltelige beskyttelsesgrupper, og R4 står for alkyl med 35 1-5 C-atomer eller aralkyl med 7-9 C-atomer, eller med acrylsyreestere med formlen V, 6 DK 174386 B1 COOR4 CK2 = C (V) NH-Y' 5 hvor Y1 og R4 har ovenstående betydning, til forbindelser med formlen VI, B1 COOR4 10 \-ch2 - C (VI) A^0 nh'y'Y'-HtJ XC00R4 wherein X 'represents a nucleofuge group, preferably chlorine or bromine, Y1 stands for alkanoyl having 1-5 C atoms, aroyl having 7-9 C atoms or others in the peptide chemistry common, acid-leaving protecting groups, and R 4 represents alkyl of 1 to 5 C atoms or aralkyl of 7-9 C atoms, or of acrylic acid esters of formula V, wherein Y1 and R4 has the above meaning, for compounds of formula VI, B1 COOR4 10 \ -ch 2 - C (VI) A ^ 0 nh'y '

A ^ OA ^ O

hvor A, B1, R4 og Y1 har ovenstående betydning, som cycli-15 seres til forbindelser med formlen Vila eller b ved hjælp af stærke syrer under acrylamid- og esterspaltning B1 20 (Vila)wherein A, B1, R4 and Y1 have the above meaning cyclized to compounds of formula Vila or b by strong acids during acrylamide and ester cleavage B1 20 (Vila)

COORCOOR

B1·.B1 ·.

25 A -^O^COOH (VIIbl i25 A - ^ O ^ COOH (VIIbl i

HH

hvor A og B1 har ovenstående betydninger, og derpå overføres disse ved katalytisk hydrogenering i nærværelse af over-30 gangsmetalkatalysatorer eller ved reduktion med boran-amin-komplekser eller komplekse borhydrider i lavere alkoholer til forbindelser med formlerne la og Ib, i hvilke R står for hydrogen, og forestres til forbindelser med formlerne la og Ib, i hvilke R har den ovenfor definerede betydning.wherein A and B1 have the above meanings, and then they are transferred by catalytic hydrogenation in the presence of transition metal catalysts or by reduction with borane-amine complexes or lower-alcohol borohydrides to compounds of formulas Ia and Ib in which R stands for hydrogen, and esterified to compounds of formulas Ia and Ib in which R has the meaning defined above.

35 Racemiske bicycliske imino-a-carboxylsyrer med form lerne la og Ib, i hvilke A og betyder hydrogen, og og 7 DK 174386 B1Racemic bicyclic imino-α-carboxylic acids of formulas Ia and Ib, in which A and means hydrogen, and and

C tilsammen betyder den ovenfor under a) nævnte kæde, kan eksempelvis fremtilles ud fra forbindelser med formlen VIIIC together means the chain mentioned above under (a), for example, can be prepared from compounds of formula VIII

E2 CE2 C

H-\—L HH - \ - L H

/ \ (VIII) zr i/ \ (VIII) zr i

HH

i hvilken brohoved H-atomerne er cis- eller trans-orien- 2 10 teret i forhold til hinanden, og B og c har ovenstående betydning.in which the bridging H atoms are cis- or trans-oriented relative to each other, and B and c have the above meaning.

Forbindelser med formlen VIII med n = 1 er kendt fra R. Griot, Helv. Chim. Acta, £2, 67 (1959), og sådanne med n = 2 er kendt fra C.M. Rice et al., J. Org. Chem., 15 21, 1687 (1955).Compounds of formula VIII with n = 1 are known from R. Griot, Helv. Chim. Acta, £ 2, 67 (1959), and such with n = 2 are known from C.M. Rice et al., J. Org. Chem., 21, 1687 (1955).

Disse forbindelser med formlen VIII acyleres på kendt måde, idet en aliphatisk eller aromatisk acyl-gruppe, fortrinsvis en acetyl- eller benzoylgruppe, bindes til nitrogenatomet, og -de opnåede N-acylerede forbindelser oxideres 20 anodisk i en aliphatisk alkohol, fortrinsvis en alkohol med 1-4 C-atomer, især methanol, i nærværelse af et ledende salt og fortrinsvis ved temperaturer i området fra 0°C til +40°C under dannelse af en forbindelse med formlen IXThese compounds of formula VIII are acylated in a known manner, wherein an aliphatic or aromatic acyl group, preferably an acetyl or benzoyl group, is bonded to the nitrogen atom and the N-acylated compounds obtained are anodically oxidized in an aliphatic alcohol, preferably an alcohol of 1-4 C atoms, especially methanol, in the presence of a conductive salt and preferably at temperatures in the range of 0 ° C to + 40 ° C to form a compound of formula IX

25 0 ir c K_\_Z H (IX) OK3 \ 30 Acyl hvori B2 og C har ovenstående betydning, og R5 betyder (C^-C4)-alkyl (analogt med Liebigs Ann. Chem., 1978. s. 1719).Acyl wherein B2 and C are as defined above and R5 is (C1-C4) alkyl (analogous to Liebigs Ann. Chem., 1978. p. 1719).

Den opnåede forbindelse med den almene formel IX omsættes ifølge Tetrahedron Letters, 1981, s. 141, med 35 trimethylsilylcyanid i et carbonhydrid, halogencarbonhydrid, i ether eller i THF ved temperaturer i området fra -60°C til +20°C, fortrinsvis -40°C til + 0°C i nærværelse af 8 DK 174386 B1 en Lewis-syre, såsom ZnCl2, SnCl2, SnCl4, TiCl4,The compound of general formula IX obtained is reacted, according to Tetrahedron Letters, 1981, p.141, with 35 trimethylsilyl cyanide in a hydrocarbon, halohydrocarbon, in ether or in THF at temperatures ranging from -60 ° C to + 20 ° C, preferably - 40 ° C to + 0 ° C in the presence of a Lewis acid such as ZnCl2, SnCl2, SnCl4, TiCl4,

BF^-etherat, fortrinsvis BF3-etherat, og den opnåede forbindelse med formlen XBF 3 etherate, preferably BF 3 etherate, and the obtained compound of formula X

n 2 5 B c (X) •'tf:, \n 2 5 B c (X) • 'tf :, \

Acyl 10 hvori brohoved H-atomerne er i cis- eller trans-stilling i forhold til hinanden, idet CN-gruppen er i cis-stilling 2 til brohoved-H-atornet på C-atom (4+n), og hvori η, B og C har den ovennævnte betydning, efter rensning og adskillelse 15 af diastereomerblandingen ved hjælp af omkrystallisation eller søjlechromatografi gennem indvirkning af syrer eller baser på kendt måde hydrolyseres til en forbindelse med formlerne la og Ib med R = hydrogen, og sidstnævnte forestres. Som syre til den sure hydrolyse af nitril-20 gruppen anvendes især HC1 eller HBr. Forestringerne gennemføres her som i det følgende ifølge de i aminosyrekemien gængse fremgangsmåder.Acyl 10 wherein the bridgehead H atoms are in cis or trans position relative to each other, the CN group being in cis position 2 to the bridgehead H atom on the C atom (4 + n), and wherein η, B and C have the above meaning, after purification and separation of the diastereomer mixture by recrystallization or column chromatography by the action of acids or bases in a known manner hydrolyzed to a compound of formulas Ia and Ib with R = hydrogen and the latter esterified. Particularly used as the acid for the acid hydrolysis of the nitrile group is HCl or HBr. The esterifications are carried out here as follows in accordance with the methods common to the amino acid chemistry.

Opfindelsen angår endvidere hidtil ukendte optisk ensartede, bicycliske imino-a-carboxylsyreestere med formlen 25 I'a eller I'b, som er ejendommelige ved, at de to brohoved-hydrogenatomer er i cis-konfiguration, COOR-gruppen er i endo-stilling i forhold til det bicycliske ringsystem, det til COOR-gruppe α-stillede C-atom har R- eller S-konfigura-tion, R betyder alkyl med 1-6 C-atomer, cycloalkyl med 4-8 30 C-atomer eller aralkyl med 7-13 C-atomer, som eventuelt kan være substitueret med NO2, og 35 9 DK 174386 B1 a) A og B^ betyder hydrogen, og 2 B og C danner tilsammen en kæde med formlen me<^ n = e^er 6 eller en kæde med formlen -(CH~) -CH=CH-(CH-) - med (p+q) = 1, 5 2, 3 eller 4, eller 2 b) C og B betyder hydrogen, og A og B1 danner tilsammen en af de ovenstående under a) definerede kæder med n = 3, 5 eller 6 eller (p+q) =1, 2, 3 eller 4, samt disses hydrochlorid-10 eller tosylatsalte.The invention further relates to novel optically uniform bicyclic imino-α-carboxylic acid esters of formula 25 Ia or Ib, which are characterized in that the two bridgehead hydrogen atoms are in cis configuration, the COOR group is in the endo position. relative to the bicyclic ring system, the C atom positioned for the COOR group α has R or S configuration, R means alkyl of 1-6 C atoms, cycloalkyl of 4-8 C atoms or aralkyl with 7-13 C atoms, which may be optionally substituted with NO2, and 35 a) hydrogen and 2B and C together form a chain of formula with <n = e 6 or a chain of the formula - (CH ~) -CH = CH- (CH-) - with (p + q) = 1, 5 2, 3 or 4, or 2 b) C and B are hydrogen, and A and B1 together form one of the chains defined under (a) above with n = 3, 5 or 6 or (p + q) = 1, 2, 3 or 4, and their hydrochloride-10 or tosylate salts.

Opfindelsen angår endvidere et diastereomert salt af en forbindelse med formlen l'a eller I'b, som er ejendommelig ved, at det diastereomere salt er i form af en N-acyleret, optisk aktiv R- eller S-aminocarboxylsyre, som indeholder 15 en phenylkerne, og som er beskyttet med alkanoyl med 1-6 C-atomer, tert.butoxycarbonyl, benzyloxycarbonyl eller andre i peptidkemien gængse NH2-beskyttelsesgrupper, og eventuelt tilstedeværende, frie OH-funktioner i de N-acylerede aminosyrer eventuelt er beskyttet med alkyl med 1-6 C-atomer, 20 benzyl eller andre i peptidkemien gængse OH-beskyttelses-grupper.The invention further relates to a diastereomeric salt of a compound of formula Ia or I'b, characterized in that the diastereomeric salt is in the form of an N-acylated optically active R- or S-aminocarboxylic acid containing a the phenyl nuclei, and which are protected by alkanoyl having 1-6 C atoms, tert-butoxycarbonyl, benzyloxycarbonyl or other NH 2 protecting groups present in the peptide chemistry, and optionally free OH functions present in the N-acylated amino acids optionally protected by alkyl with 1-6 C atoms, 20 benzyl or others in the peptide chemistry common OH protecting groups.

De optisk rene forbindelser med formlen la eller Ib er anvendelige ved en fremgangsmåde til fremtilling af optisk rene forbindelser med de almene formler Ila eller Ilb 25 1 o b' b- c \/ / 35 CCOi! (Ila)The optically pure compounds of the formula Ia or Ib are useful in a process for preparing optically pure compounds of the general formulas Ila or IIb 25 o b 'b- c \ / / 35 CCO 1! (IIa)

Λ XNX ^ HΛ XNX ^ H

30 I Y30 I Y

I * * . 1I * *. 1

0 = c - CH - HH - CH - £CH^7 - C - X0 = c - CH - HH - CH - £ CH ^ 7 - C - X

I 1 r iI 1 r i

1 2 R CC^IT Z1 2 R CC ^ IT Z

10 DK 174386 B110 DK 174386 B1

B1 B2 CB1 B2 C

(iib)(IIb)

A COOHA COOH

5 1 » .· I5 1 ». · I

O = C - CH - HH - CH - ZCH_7 - C - '( ‘i j ? i R co2rz z 10 i hvilke de med en stjerne (*-) markerede carbonatomer hver gang uafhængigt af hinanden kan udvise R- eller S-konfigurationen, a) A og betyder hydrogen, og 2 B og C danner tilsammen en kæde med formlen 15 -(C^) - med n = 3, 4, 5 eller 6 eller en kæde med formlen - (CHj)p-CH-CH-(CH2> - med (p+q) = 1, 2, 3 eller 4, eller 2 b) C og B betyder hydrogen, og A og danner tilsammen en kæde med formlen 20 -(CI^^- mec^ n = ^ eller 6 eller en kæde med formlen -(CI^)p-CH=CH-(CH2)g- med (p+q) =1, 2, 3 eller 4, eller c) A og C betyder hydrogen, og 1 2 B og B danner tilsammen en kæde med formlen 25 -(CH2)m~ med m = 4, 5, 6 eller 7, r = 0 eller 1, = hydrogen, en eventuelt substitueret aliphatisk gruppe med 1-6 C-atomer, en eventuelt substitueret alicyclisk gruppe med 3-9 C-atomer, en eventuelt substitueret ali-30 cyclisk-aliphatisk gruppe med 4-11 C-atomer, en eventuelt substitueret aromatisk gruppe med 6-12 C-atomer, som også kan være delvist hydrogeneret, en eventuelt substitueret araliphatisk gruppe med 7-15 C-atomer, en eventuelt substitueret aroylaliphatisk gruppe med 8-13 C-atomer, 35 en eventuelt substitueret mono- eller bicyclisk hetero- cyclisk gruppe med 5-7 eller 8-10 ringatomer, hvoraf 11 DK 174386 B1 1-2 ringatoraer er svovl- eller oxygenatomer og/eller hvoraf 1-4 ringatomer er nitrogenatomer, eller en sidekæde af en naturligt forekommende, eventuelt beskyttet aminosyre, 2 5 R = hydrogen, en eventuelt substitueret aliphatisk gruppe med 1-6 C-atomer eller en eventuelt substitueret aliphatisk gruppe med 7-15 C-atomer, Y = hydrogen eller hydroxy, Z = hydrogen eller 10 Y og Z = tilsammen oxygen, ogO = C - CH - HH - CH - ZCH_7 - C - '(' ij? I R co2rz z 10 in which the carbon atoms marked with an asterisk (* -) can exhibit each time the R or S configuration independently of each other, a) A and means hydrogen, and 2 B and C together form a chain of formula 15 - (C 2) - with n = 3, 4, 5 or 6 or a chain of formula - (CH 2) p-CH-CH- (CH 2> - with (p + q) = 1, 2, 3 or 4, or 2 b) C and B represent hydrogen and A and together form a chain of formula 20 - (C or 6 or a chain of formula - (C1-6) p-CH = CH- (CH2) g- with (p + q) = 1, 2, 3 or 4, or c) A and C are hydrogen, and 1 2 B and B together form a chain of formula 25 - (CH 2) m - with m = 4, 5, 6 or 7, r = 0 or 1, = hydrogen, an optionally substituted aliphatic group having 1-6 C atoms, a optionally substituted alicyclic group having 3-9 C atoms, an optionally substituted alicyclic aliphatic group having 4-11 C atoms, an optionally substituted aromatic group having 6-12 C atoms, which may also be re partially hydrogenated, an optionally substituted araliphatic group having 7-15 C atoms, an optionally substituted aroylaliphatic group having 8-13 C atoms, an optionally substituted mono- or bicyclic heterocyclic group having 5-7 or 8-10 ring atoms, of which 11 are ring sulfur or oxygen atoms and / or of which 1-4 ring atoms are nitrogen atoms, or a side chain of a naturally occurring, optionally protected amino acid, R = hydrogen, an optionally substituted aliphatic group with 1-6 C atoms or an optionally substituted aliphatic group having 7-15 C atoms, Y = hydrogen or hydroxy, Z = hydrogen or 10 Y and Z = combined oxygen, and

X = en aliphatisk gruppe med 1-6 C-atomer, en alicyclisk gruppe med 5-9 C-atomer, en eventuelt substitueret aromatisk gruppe med 6-12 C-atomer eller indoyl, ved en fremgangsmåde, ved hvilken man omsætter optisk rene 15 forbindelser med formlen la eller Ib, i hvilke R, A, B1, B2 og C har ovennævnte betydning, med optisk rene forbindelser med formlen IIIX = an aliphatic group having 1-6 C atoms, an alicyclic group having 5-9 C atoms, an optionally substituted aromatic group having 6-12 C atoms, or indoyl, by a process of reacting optically pure 15 compounds of formula Ia or Ib, in which R, A, B1, B2 and C have the above meaning, with optically pure compounds of formula III

* * y HOOC - CH - NH - CH - [CH01 - C - X (III)* * y HOOC - CH - NH - CH - [CH01 - C - X (III)

20 I, I ? 2 Γ I20 I, I? 2 Γ I

R C02R ZR CO 2 R Z

35 hvilken de to C-atomer, som er markeret med en stjerne (*), 2 udviser (S,R), (R,S), (R,R) eller fortrinsvis (S,S) konfi- X 2 25 guration, og r, R , R , X, Y og Z har ovennævnte betydning, i nærværelse af et kondensationsmiddel eller eventuelt som aktiv ester, derpå fraspaltes gruppen R ved hydrogenolyse eller hydrolyse, og de optisk rene forbindelser med formlerne Ila og Ilb overøres eventuelt i fysiologisk 30 tålelige salte.Wherein the two C atoms marked with an asterisk (2) have 2 (S, R), (R, S), (R, R) or preferably (S, S) configurations. and R, R, R, X, Y and Z are as defined above, in the presence of a condensing agent or optionally as an active ester, then the group R is decomposed by hydrogenolysis or hydrolysis, and the optically pure compounds of formulas IIa and IIb are optionally stirred in physiologically tolerable salts.

Ved en foretrukken udførelsesform for denne fremgangsmåde fremstilles forbindelser med formlerne Ila eller Ilb, i hvilke r = 0 eller 1, 12 DK 174386 B1 R^· = hydrogen eller C^-Cg-alkyl, som eventuelt kan være substitueret med amino, C^-Cg-acylamino eller benzoyl-amino, C^-Cg-alkenyl, Cg-C^-cycloalkyl, Cg-Cg-cycloalke-nyl, C5-c^-cycloalkyl-(C-^-C^)-alkyl, aryl eller delvist 5 hydrogeneret aryl med 6-12 C-atomer, som hver gang kan være substitueret med C^-C4~alkyl, C1-C2~ulkoxy eller halogen, Cg-C^-aryl- ) -alkyl eller C^-C^^-aroyl-(C^-C2)-alkyl, hvor begge kan være substitueret i arylgruppen som ovenfor defineret, en 10 mono- eller bicyclisk heterocyclisk gruppe med henholds vis 5-7 og 8-10 ringatomer, hvoraf 1-2 ringatomer er svovl- eller oxygenatomer, og/eller hvoraf 1-4 ringatomer er nitrogenatomer, eller en eventuelt beskyttet sidekæde af en naturligt forekommende aminosyre, 2 15 R = hydrogen, C^-Cg-alkyl, C-^-Cg-alkenyl eller Cg-C12--aryl-(C^-C4)-alkyl, Y = hydrogen eller hydroxy, Z = hydrogen, eller Y og Z = tilsammen oxygen, og 20 x = C-^-Cg-alkyl , C2-Cg-alkenyl, C^-Cg-cycloalkyl,In a preferred embodiment of this process, compounds of formulas IIa or IIb are prepared in which r = 0 or 1, hydrogen or C 1 -C 6 alkyl, which may be optionally substituted with amino, C -Cg-acylamino or benzoylamino, C ^-Cg-alkenyl, Cg-C ^-cycloalkyl, Cg-Cg-cycloalkenyl, C5-C ^-cycloalkyl (C --C ^) -alkyl, aryl or partially hydrogenated aryl having 6-12 C atoms which may each be substituted by C1-C4 alkyl, C1-C2 ulkoxy or halogen, C8 -C4 -aryl-) alkyl or C1-C 3 - aroyl (C 1 -C 2) alkyl, both of which may be substituted in the aryl group as defined above, a mono- or bicyclic heterocyclic group having 5-7 and 8-10 ring atoms, respectively, of which 1-2 ring atoms are sulfur or oxygen atoms, and / or of which 1-4 ring atoms are nitrogen atoms, or an optionally protected side chain of a naturally occurring amino acid, R = hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl or C 6 -C 12 - aryl (C 1 -C 4) alkyl, Y = hydrogen or hy droxy, Z = hydrogen, or Y and Z = combined oxygen, and 20 x = C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 1 -C 8 cycloalkyl,

Cg-C^-aryl, som kan være mono-, di- eller trisub-stitueret med C^-C^-alkylamino, di-(C^-C4)-alkylamino, C^-C4-alkyl, C^-C^-alkoxy, hydroxy, halogen, nitro, amino og/eller methylendioxy, eller 3-indolyl.Cg-C ^ -aryl which may be mono-, di- or trisubstituted with C C-C ^ alkylamino, di- (C ^-C4) alkylamino, C ^-C4 alkyl, C ^-C N -alkoxy, hydroxy, halogen, nitro, amino and / or methylenedioxy, or 3-indolyl.

25 Foretrukken er fremstillingen af S,S,S-forbindelserne med formlen Ila.Preferred is the preparation of the S, S, S compounds of formula IIa.

Ved aryl skal der her og i det følgende fortrinsvis forstås eventuelt substitueret phenyl eller naphthyl. Alkyl kan være ligekædet eller forgrenet.By aryl, here and hereinafter is preferably understood to be optionally substituted phenyl or naphthyl. Alkyl may be straight or branched.

30 Ved en mono- eller bicyclisk heterocyclisk gruppe med henholdsvis 5-7 og 8-10 ringatomer, i hvilken ringatomerne har de ovenfor nævnte betydninger, forstås eksempelvis thienyl, benzolb]-thienyl, furyl, pyranyl, benzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, 35 pyridazinyl, indazolyl, isoindolyl, indolyl, pyrinyl, quinolizinyl, isoquinolinyl, phthalazinyl, naphthydridinyl, 13 DK 174386 B1 quinoxalinyl, quinazolyl, cinnolinyl, pteridinyl, oxazolyl, isoxazolyl, thiazolyl eller isothiazolyl. Disse grupper kan også vare delvist eller fuldstændigt hydrogeneret.By a mono- or bicyclic heterocyclic group having 5-7 and 8-10 ring atoms, respectively, in which the ring atoms have the above meanings are understood, for example, thienyl, benzolb] -thienyl, furyl, pyranyl, benzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, indazolyl, isoindolyl, indolyl, pyrinyl, quinolizinyl, isoquinolinyl, phthalazinyl, naphthydridinyl, quinoxalinyl, quinazolyl, cinnolinyl, pteridinyl, pteridinyl, oxterol These groups may also be partially or completely hydrogenated.

Såfremt står for en sidekæde af en beskyttet 5 naturligt forekommende α-aminosyre, f.eks, beskyttet eller eventuelt substitueret Ser, Thr, Asp, Asn, Glu, Gin, Arg,If it represents a side chain of a protected naturally occurring α-amino acid, for example, protected or optionally substituted Ser, Thr, Asp, Asn, Glu, Gln, Arg,

Lys, Hyl, Cys, Orn, Cit, Tyr, Trp, His eller Hyp, foretrækkes der som beskyttelsesgrupper de i peptidkemien gængse grupper (jfr. Houben-Weyl, Bd. XV/1 og XV/2). I 10 tilfælde af, at b} betyder den beskyttede lysin-sidekæde, foretrækkes de kendte amino-beskyttelsesgrupper, men især C-^-Cg-alkanoyl. Foretrukne O-beskyttelsesgrupper for tyrosin er methyl eller ethyl.Lys, Hyl, Cys, Orn, Cit, Tyr, Trp, His or Hyp, as protecting groups, are preferred groups in the peptide chemistry (cf. Houben-Weyl, Vol. XV / 1 and XV / 2). In 10 cases where b} means the protected lysine side chain, the known amino protecting groups are preferred, but especially C 1-6 C 8 alkanoyl. Preferred O-protecting groups for tyrosine are methyl or ethyl.

Ved de hidtil kendte fremgangsmåder, hvor der gås uu 15 fra stereoisomere blandinger, og som tjente til fremstilling af stereoisomere blandinger af forbindelser med formlerne Ila eller Ilb, var det nødvendigt at adskille reaktionsblandingen ved besværlige separationsprocesser for at få den ønskede optisk rene stereoisomer med formlen Ila eller Ilb. 20 Ved omsætning af de optisk ensartede imino-a-carb- oxylsyreestere med formlen la eller Ib med optisk ensartede forbindelser med formlen III er den direkte syntese af optisk ensartede forbindelser med formlen Ila eller Ilb blevet mulig. De ønskede forbindelser med formlerne Ila eller Ilb 25 fås i høje udbytter uden anvendelse af besværlige adskillelsesmetoder .In the known methods, where uu 15 is derived from stereoisomeric mixtures, and which served to prepare stereoisomeric mixtures of compounds of formulas IIa or IIb, it was necessary to separate the reaction mixture by cumbersome separation processes to obtain the desired optically pure stereoisomer of the formula Ila or Ilb. By reacting the optically uniform imino-α-carboxylic acid esters of formula Ia or Ib with optically uniform compounds of formula III, the direct synthesis of optically uniform compounds of formula IIa or IIb has become possible. The desired compounds of formulas IIa or IIb 25 are obtained in high yields without the use of cumbersome separation methods.

Forbindelser med formlen III er beskrevet i de foran nævnte dokumenter, eller de er kendte fra EP-offentliggø-relsesskrift nr. 46.953. Omsætningen af en forbindelse med 30 formlen III med l-(2of,3aft, 7aS)-octahydro- [IH] -indol-2-carboxylsyre -tert.butylester og den følgende fraspaltning af en tert.butylester, hvilket resulterer i et tilsvarende oc-tahydroindol-derivat med formlen Ilb, er kendt fra EP-of-fentliggørelsesskrift nr. 37.231.Compounds of formula III are described in the aforementioned documents or are known from EP Publication No. 46,953. The reaction of a compound of formula III with 1- (2of, 3aphth, 7aS) -octahydro- [1H] -indole-2-carboxylic acid-tert-butyl ester and the subsequent decomposition of a tert-butyl ester resulting in a corresponding -tahydroindole derivative of formula IIb, is known from EP Publication No. 37,231.

35 Denne omsætning er imidlertid begrænset til omsætning af en forbindelse med formlen la eller Ib, hvor C og 14 DK 174386 B1 hver især betyder H, og A + B1 er (CH2)4/ hvilken forbindelse hidtil kun har kunnet fremtilles på omstændig måde via N-benzoylforbindelsen, krystallisation af de diastereomere salte med S-ar-phenylethylamin, frigørelse af N-benzoylfor-5 bindeisen, fraspaltning af benzoylgruppen og forestring.However, this reaction is limited to the reaction of a compound of formula Ia or Ib, wherein C and B are each meaning H, and A + B1 is (CH2) 4 / which compound has hitherto only been able to be prepared in a The N-benzoyl compound, crystallization of the diastereomeric salts with S-ar-phenylethylamine, release of the N-benzoyl compound ice, cleavage of the benzoyl group and esterification.

Overførelsen af denne reaktionsfølge på forbindelser med formlen la og Ib er hidtil ikke lykkedes. Også adskillelsen af racemiske blandinger af forbindelser med formlen Ila og IIb ved adskillelse af gængse diastereoisomere salte 10 med optisk aktive carboxyl- eller sulfosyrer lykkes ikke.The transfer of this reaction sequence to compounds of formula Ia and Ib has so far been unsuccessful. Also, the separation of racemic mixtures of compounds of formula Ila and IIb by separation of conventional diastereoisomeric salts 10 with optically active carboxylic or sulfo acids is not successful.

Først ved den her omhandlede fremgangsmåde er forbindelserne med formlen la og Ib blevet tilgængelige for efterfølgende reaktioner.Only by the process of the present invention have the compounds of formula Ia and Ib become available for subsequent reactions.

Fremgangsmåden til omdannelse af forbindelser med 15 formel la eller Ib til forbindelser med formel Ila eller IIb er særlig økonomisk, da forbindelser med formlen III ifølge DE-offentliggørelsesskrift nr. 32 26 768 kan fremstilles direkte på optisk ren form på simpel måde. Ifølge den deri beskrevne teknik må disse mellemprodukter imidlertid 20 omsættes med endnu en racemisk aminosyre og overføres i et yderligere oprensningstrin i en optisk ren forbindelse med den almene formel Ila eller Ilb.The process for converting compounds of formula Ia or Ib into compounds of formula Ila or IIb is particularly economical, since compounds of formula III according to DE Publication No. 32 26 768 can be prepared directly in optically pure form in a simple manner. However, according to the technique described therein, these intermediates must be reacted with yet another racemic amino acid and transferred in a further purification step in an optically pure compound of the general formula IIa or IIb.

Den ovenfor beskrevne fremgangsmåde, som fortrinsvis gennemføres med S,S-forbindelser med formlen III, udgør 25 følgelig den langt mest økonomiske fremgangsmåde til fremstilling af forbindelser med formel Ila eller Ilb, da man ved alle andre kendte fremgangsmåder må finde sig i høje tab ved chromatografi eller krystallisation af delvis komplekse stereoisomerblandinger.Accordingly, the process described above, which is preferably carried out with S, S compounds of formula III, is by far the most economical process for the preparation of compounds of formula IIa or IIb, since in all other known processes one must find at high losses at chromatography or crystallization of partially complex stereoisomer mixtures.

30 Kondensationstrinnet sker ifølge en af de gængse, næsten racemiseringsfrit forløbende fremgangsmåder til peptidsyntese, som er beskrevet i f.eks. Houben-Weyl, Bd. XV, eller i "The Peptide, Analyses, Synthesis, Biology, Vol. 1,The condensation step is performed according to one of the conventional, almost racemization-free, peptide synthesis procedures described in e.g. Houben-Weyl, Vol. XV, or in "The Peptide, Assays, Synthesis, Biology, Vol. 1,

Major Methods of Peptide Bond Formation, Part A", Gross, 35 Meierhofer, Academic Press N.Y. (1979). Særlig fordelagtig er DCC/HOBt-metoden, ifølge Chem. Ber., 103 (1979), side 15 DK 174386 B1 788-798. Herved skal der tages hensyn til, at reaktionsdygtige funktionelle grupper i gruppen R1 skal beskyttes forbigående ifølge kendte metoder fra peptidkemien (f.eks. Houben-Weyl, Bd. XV, eller Bodanszky et al. i "Peptide Syn-5 thesis", 2. Auflage (1976), John Wiley & Sons).Major Methods of Peptide Bond Formation, Part A ", Gross, 35 Meierhofer, Academic Press NY (1979). Particularly advantageous is the DCC / HOBt method, according to Chem. Ber., 103 (1979), page 15 DK 174386 B1 788. 798. This should take into account that reactive functional groups in the group R1 are to be transiently protected according to known methods from the peptide chemistry (e.g. Houben-Weyl, Vol. XV, or Bodanszky et al. In "Peptide Synthesis"). , 2nd Edition (1976), John Wiley & Sons).

De optisk ensartede forbindelser med formlen Ila eller Ilb fås på i og for sig kendt måde ved fraspaltning af R og eventuelt R2 i højt udbytte uden anvendelse af besværlige adskillelsesmetoder.The optically uniform compounds of formula IIa or IIb are obtained in a manner known per se by cleavage of R and optionally R 2 in high yield without the use of cumbersome separation methods.

10 Forbindelserne med formlen Ila eller Ilb og deres salte besidder en langvarig, intensiv blodtryksænkende virkning. De er stærke hæmmere af det angiotensinomdannende enzym (ACE) og kan anvendes til bekæmpelse af forhøjet blodtryk, der skyldes forskellige årsager. ACE-inhibitorer af 15 denne type kendes f.eks. fra US-patentskrift nr. 4.344.949 og EP-offentiiggørelsesskrifter nr. 49.658, nr. 46.953, nr. 50.850 og nr. 79.022.The compounds of formula Ila or Ilb and their salts have a long-lasting, intensive blood pressure lowering effect. They are potent inhibitors of the angiotensin converting enzyme (ACE) and can be used to fight high blood pressure due to various causes. ACE inhibitors of this type are known e.g. from U.S. Patent No. 4,344,949 and EP Publication Nos. 49,658, No. 46,953, No. 50,850, and No. 79,022.

Det er også muligt at kombinere disse forbindelser med andre blodtryksænkende, karudvidende eller diuretisk 20 aktive forbindelser. Typiske repræsentanter for disse klasser af aktive forbindelser er f.eks. beskrevet i Erhardt-Ruschig, Arzneimittel, 2. Auflage, Weinhein, (1972). Anvendelsen kan ske intravenøst, subcutant eller peroralt.It is also possible to combine these compounds with other blood pressure lowering, vasodilator or diuretic active compounds. Typical representatives of these classes of active compounds are e.g. described in Erhardt-Ruschig, Arzneimittel, 2. Auflage, Weinhein, (1972). The use can be done intravenously, subcutaneously or orally.

Ved oral indgivning ligger doseringen sædvanligvis 25 ved 1-500 mg, fortrinsvis ved 1-100 mg, i hver enkelt dosis til en voksen patient med normalvægt . I alvorlige tilfælde kan doserne forhøjes, da der hidtil ikke er observeret toksiske egenskaber. Også en nedsættelse af dosen er mulig og fremfor alt rimelig, når der samtidig indgives diuretika.For oral administration, the dosage is usually 25 to 1-500 mg, preferably 1-100 mg, in each dose to a normal adult adult patient. In severe cases, the doses may be increased as no toxic properties have been observed so far. Also, a dose reduction is possible and above all reasonable when concomitant diuretics are administered.

30 Forbindelserne kan gives oralt eller parenteralt i passende farmaceutisk tilberedning. Til en oral anvendelsesform blandes de aktive forbindelser med de dertil gængse tilsætningsstoffer, f.eks. bærestoffer, stabilisatorer eller indifferente fortyndingsmidler, og bringes ved gængse metoder 35 på en egnet indgivelsesform, såsom tabletter, dragées, stikkapsler, vandige, alkoholiske eller oliebaserede suspensioner 16 DK 174386 B1 eller vandige, alkoholiske eller oliebaserede opløsninger.The compounds can be given orally or parenterally in appropriate pharmaceutical preparation. For an oral use, the active compounds are mixed with the usual additives, e.g. carriers, stabilizers or inert diluents, and are applied by conventional methods 35 to a suitable form of administration such as tablets, dragees, sachets, aqueous, alcoholic or oil-based suspensions or aqueous, alcoholic or oil-based solutions.

Som indifferent bærer kan f.eks. anvendes gummiarabicum, magnesiumcarbonat, kaliumphosphat, mælkesukker, glucose eller stivelse, især majsstivelse. Derved kan tilberedningen 5 ske som både tørt eller fugtigt granulat. Som olieagtige bærestoffer eller opløsningsmidler kommer eksempelvis vegetabilske eller animalske olier i betragtning, såsom solsikkeolie eller levertran.As an inert carrier, e.g. gum arabic, magnesium carbonate, potassium phosphate, milk sugar, glucose or starch, especially corn starch are used. Thereby, the preparation 5 can be made as both dry or moist granulate. Vegetable or animal oils, such as sunflower oil or liver oil, are considered as oily carriers or solvents.

Til den subcutane eller intravenøse anvendelse bringes 10 de aktive forbindelser eller deres fysiologisk tålelige salte om ønsket sammen med de dertil gængse substanser, såsom opløsningsformidlere, emulgatorer eller yderligere hjælpestoffer, i opløsning, suspension eller emulsion. Som opløsningsmiddel for de aktive forbindelser og de tilsvarende 15 fysiologisk tålelige salte kommer eksempelvis følgende på tale: vand, fysiologiske kogsaltopløsninger eller alkoholer, f.eks. ethanol, propandiol eller glycerol, desuden også sukkeropløsninger, såsom glucose- eller mannitolopløsninger, eller en blanding af de forskellige nævnte opløsningsmidler 20 eller opløsninger.For the subcutaneous or intravenous use, the active compounds or their physiologically tolerable salts, if desired, are brought into solution, suspension or emulsion with the usual substances, such as solvents, emulsifiers or additional excipients. As the solvent for the active compounds and the corresponding physiologically tolerable salts, for example, the following are mentioned: water, physiological saline solutions or alcohols, e.g. ethanol, propanediol or glycerol, in addition also sugar solutions, such as glucose or mannitol solutions, or a mixture of the various solvents mentioned or solutions.

De følgende eksempler belyser opfindelsen, idet eksempel 1-12 illustrerer fremstillingen af forbindelser med formel la eller Ib, og eksempel 13-17 illustrerer disses omdannelse til biologisk aktive forbindelser med formel Ila 25 eller Ilb.The following examples illustrate the invention, Examples 1-12 illustrating the preparation of compounds of formula Ia or Ib, and Examples 13-17 illustrating their conversion to biologically active compounds of formula Ila 25 or Ilb.

Eksempel 1 (1S,3S,5S)-2-Azabicyclo[3.3.0]octan-3-carboxylsyre-benzyl- ester-hydrochlorid (forkortelse (S)~Aoc-OBzl-KCl)_ 30 (A) 2-Acetylamino-3-(2-oxo-cyclopentyl)-propion- _syremethylester_ 269 g 3-chlor-2-acetyl-amino-propionsyremethylester og 257 g cyclopentenopyrrolidin holdes i 24 timer ved stuetemperatur i 1,5 liter DMF. Der koncentreres i vakuum, 35 remanensen optages i lidt vand, med koncentreret saltsyre indstilles pH på 2, og der ekstraheres 2 gange med hver 17 DK 174386 B1 gang 4 liter ethylacetat. Ved koncentreringen af den organiske fase bliver der en lysegul olie tilbage.Example 1 (1S, 3S, 5S) -2-Azabicyclo [3.3.0] octane-3-carboxylic acid benzyl ester hydrochloride (Abbreviation (S) ~ Aoc-OBzl-KCl) (A) 2-Acetylamino 3- (2-oxo-cyclopentyl) -propionic acid methyl ester 269 g of 3-chloro-2-acetylamino-propionic acid methyl ester and 257 g of cyclopentenopyrrolidine are kept for 24 hours at room temperature in 1.5 liters of DMF. It is concentrated in vacuo, the residue is taken up in a little water, the pH is adjusted to 2 with concentrated hydrochloric acid and extracted twice with 4 liters of ethyl acetate each 17 times. When the organic phase is concentrated, a pale yellow oil remains.

Udbytte: 290 g.Yield: 290 g.

1H-NMR: 2,02 (s,3H); 3,74 (s,3H); 4,4-4,8 (CDCl^1 H-NMR: 2.02 (s, 3H); 3.74 (s, 3H); 4.4-4.8 (CDCl

5 Analyse: C Η NAnalysis: C Η N

beregnet: 58,1 7,54 6,16 fundet: 58,5 7,2 6,5 (B) cis,endo-2-Azabicyclo-[3.3.0]-octan-3-carboxyΙ- ΙΟ _syre-hydrochlor id______ 270 g af det under (A) fremstillede acetylamino-derivat koges under tilbagesvaling i 1,5 liter 2N saltsyre i 45 minutter. Der koncentreres i vakuum, remanensen optages i iseddike, der tilsættes 5 g Pt/'C (10% Pt) og hydrogeneres 15 ved 500 kPa. Efter filtrering koncentreres, og remanensen krystalliseres fra en blanding af chloroform og diisopropyl-ether.calculated: 58.1 7.54 6.16 Found: 58.5 7.2 6.5 (B) cis, Endo-2-Azabicyclo- [3.3.0] -octane-3-carboxyΙ-sy-acid hydrochloride 270 g of the acetylamino derivative prepared under (A) is refluxed in 1.5 liters of 2N hydrochloric acid for 45 minutes. Concentrate in vacuo, the residue is taken up in glacial acetic acid, 5 g of Pt / C (10% Pt) is added and hydrogenated at 500 kPa. After filtration, concentrate and the residue is crystallized from a mixture of chloroform and diisopropyl ether.

Smeltepunkt: 205-209°C.Melting point: 205-209 ° C.

Udbytte: 150 g.Yield: 150 g.

20 (IS,3S,5S)-2-Azabicyclo[3.3.0]octan-3-carboxylsyre-benzyl-ester-hydrochlorid (forkortelse (S)-Aoc-OBzl-HCl)_(IS, 3S, 5S) -2-Azabicyclo [3.3.0] octane-3-carboxylic acid benzyl ester hydrochloride (Abbreviation (S) -Aoc-OBzl-HCl)

(C) Racemisk Aoc-qbzI-HCI(C) Racemic Aoc-qbzI-HCl

1,2 liter (11,5 mol) benzylalkohol nedkøles til -10°C.1.2 liter (11.5 mol) of benzyl alcohol is cooled to -10 ° C.

25 Under køling og omrøring dryppes 126 ml (1,73 mol) thionyl-chlorid til, og derpå indføres under omrøring ved -10°C 126,5 g (0,66 mol) rå Aoc.HCl, og der efteromrøres i 30 minutter ved denne temperatur. Derpå får temperaturen lov til langsomt at stige til 20-25°C, idet produktet opløses 30 under omrøring inden for 5 timer. Efter henstand natten over får den brune opløsning lov til at løbe ud i 4,0 liter diisopropylether. Efter 1 time frafiltreres de udfældede krystaller, og de vaskes med diisopropylether og tørres i vakuum. Fra de forenede diisopropyletheropløsninger udfældes 35 der i løbet af natten et yderligere bundfald.During cooling and stirring, 126 ml (1.73 mole) of thionyl chloride is added dropwise and then, with stirring at -10 ° C, 126.5 g (0.66 mole) of crude Aoc.HCl is added and stirred for 30 minutes. at this temperature. Then, the temperature is allowed to slowly rise to 20-25 ° C, dissolving the product under stirring within 5 hours. After standing overnight, the brown solution is allowed to pour into 4.0 liters of diisopropyl ether. After 1 hour, the precipitated crystals are filtered off and washed with diisopropyl ether and dried in vacuo. From the combined diisopropyl ether solutions, 35 precipitates a further precipitate during the night.

Udbytte. 168,5 g (90,6%).Yield. 168.5 g (90.6%).

18 DK 174386 B118 DK 174386 B1

(D) (S)-Aoc-OBlz,Z-Phe-OH(D) (S) -Aoc-OBlz, Z-Phe-OH

166.0 g (0,589 mol) racemlsk Aoc-OBzl*HCl suspenderes i 500 ml methylenchlorid og rystes grundigt med 25 g (0,625 mol) NaOH i 250 ml vand. Der indtræder en opløsnings-5 proces. Efter kort tid skiller den først dannede emulsion sig. Man skiller methylenchloridfasen fra, vasker med 100 ml 0,1N NaOH og 2 gange med hver gang 50 ml vand og ekstraherer de forenede vandige faser 2 gange med hver gang 100 ml methylenchlorid. De samlede methylenchlorid-10 faser tørres over natriumsulfat og koncentreres skånsomt i vandstrålevakuum. Den tilbageblevne olie optages straks i 100 ml ethylacetat, og en opløsning af 117,6 g (0,39 mol) N-benzyloxycarbonyl-S~phenylalanin (Z-Phe-OH) i 200 ml ethylacetat tilsættes. Kolben vaskes efter med 100 ml 15 ethylacetat. Til den klare opløsning sættes under omrøring ved stuetemperatur 1600 ml cyclohexan (= 4-dobbelt volumen-mængde). Efter udrivning begynder krystallisationen, som fuldstændiggøres ved henstand i kølerum natten over.166.0 g (0.589 mol) of racemic Aoc-OBzl * HCl is suspended in 500 ml of methylene chloride and shaken thoroughly with 25 g (0.625 mol) of NaOH in 250 ml of water. A solution-5 process occurs. After a short time, the first emulsion forms. The methylene chloride phase is separated, washed with 100 ml of 0.1 N NaOH and twice with 50 ml of water each time, and the combined aqueous phases are extracted twice with 100 ml of methylene chloride each time. The combined methylene chloride phases are dried over sodium sulfate and concentrated gently in water jet vacuum. The residual oil is taken up immediately in 100 ml of ethyl acetate and a solution of 117.6 g (0.39 mol) of N-benzyloxycarbonyl-S-phenylalanine (Z-Phe-OH) in 200 ml of ethyl acetate is added. The flask is then washed with 100 ml of ethyl acetate. To the clear solution is added 1600 ml of cyclohexane (= 4 times the volume) with stirring at room temperature. After tearing off, crystallization begins, which is completed by standing in the refrigerator overnight.

Det krystallinske bundfald filtreres fra, vaskes med 250 ml 20 ethylacetat/cyclohexan i forholdet 1:4 og tørres.The crystalline precipitate is filtered off, washed with 250 ml of 1: 4 ethyl acetate / cyclohexane and dried.

Udbytte: 133,6 g (S)-Aoc-0Bzl*Z-Phe-OH (50,9%, svarende til 102% af teorien).Yield: 133.6 g (S) -Aoc-OBzl * Z-Phe-OH (50.9%, corresponding to 102% of theory).

Smeltepunkt: 101-103°C. [a]^ = -5,3° (c = 1, methanol).Melting point: 101-103 ° C. [α] D = -5.3 ° (c = 1, methanol).

25 Efter omkrystallisation fra en blanding af ethyl- acd^t og cyclohexan i forholdet 1:1 fås for Z-Phe-OH-saltet følgende data:After recrystallization from a mixture of ethyl acetate and cyclohexane in a 1: 1 ratio, the following data is obtained for the Z-Phe-OH salt:

Smeltepunkt: 103-104°C. [a]^ “ ~6,1° (c = 1, methanol).Melting point: 103-104 ° C. [α] D = ~ 6.1 ° (c = 1, methanol).

20 (E) (S)-Aoc-OBzl*HCl 63.0 g (0,142 mol) af det ifølge (D) opnåede Z-Phe-OH-salt opløses i 300 ml methylenchlorid og rystes godt med 6,0 g (0,15 mol) NaOH i ca. 150 ml vand. Faseadskillelsen kræver nogen tid på grund af lidt uopløst ma- 35 teriale. Methylenchloridfasen skilles fra, den vaskes med 50 ml 0,1 N NaOH, to gange med hver gang 50 ml vand og tør- 19 DK 174386 B1 res. Der koncentreres til ca. 100 ml, fortyndes med 10O ml diisopropylether, og under omrøring tilsættes 25 ml 6 N HC1 i ether. Efter 1 time filtreres, bundfaldet vaskes med diisopropylether og tørres.(E) (S) -Aoc-OBzl * HCl 63.0 g (0.142 mol) of the Z-Phe-OH salt obtained in (D) is dissolved in 300 ml of methylene chloride and shaken well with 6.0 g (0.15 mole) NaOH for approx. 150 ml of water. The phase separation requires some time due to slightly undissolved material. The methylene chloride phase is separated, washed with 50 ml of 0.1 N NaOH, twice with 50 ml of water each time and dried. Concentrate to approx. 100 ml, diluted with 10 ml of diisopropyl ether and with stirring 25 ml of 6 N HCl in ether are added. After 1 hour, filter, wash the precipitate with diisopropyl ether and dry.

5 Udbytte: 32,5 g (81,3%).Yield: 32.5 g (81.3%).

Smeltepunkt: 185-186°C.Melting point: 185-186 ° C.

[a]p° : -42,5° (c = 1, vand).[α] p °: -42.5 ° (c = 1, water).

Den basiske vandfase befries i vakuum for methylen-10 chlorid og gøres sur med koncentreret HCl. Det udfældede Z-Phe-OH vaskes med vand og tørres.The basic aqueous phase is freed in vacuo for methylene chloride and acidified with concentrated HCl. The precipitated Z-Phe-OH is washed with water and dried.

På den beskrevne måde fås R-forbindelsen fra raethylenchlorid-moderluden fra eksempel 1 (D) samt yderligere Z-Phe-OH.In the manner described, the R compound is obtained from the ethylene chloride mother liquor of Example 1 (D) as well as additional Z-Phe-OH.

% DK 174386 B1 20% DK 174386 B1 20

XX

- o o o pH vø in cn n p >. p- o o o pH add in cn n p>. p

υ CN CN rHυ CN CN rH

-p rH rr <0* eo + + +-p rH rr <0 * eo +++

PCM QPCM Q

0 O0 O

•r «i 05 υ υ υ • o o o Ωι cn m iø p ε σι æ oo• r «i 05 υ υ υ • o o o Ωι cn m iø p ε σι æ oo

Ji W pH rH rHJi W pH rH rH

3 Λ II I3 Λ II I

Ό O o on m o in σι oo ooΌ O o on m o in σι oo oo

MK pH pH rHMK pH pH rH

αα

P rHP rH

3 « O O 0 oooooo 0 pH o cn cm cn σ» o o p co cm «· CQ — » p P p P r v p3 «O O 0 oooooo 0 pH o cn cm cn σ» o o p co cm «· CQ -» p P p P r v p

E CM rH CJl OrHOOlOllD COE CM rH CJl OrHOOlOllD CO

fio ρΗττγη μ· ·<3· ^j· p cn π \ø OCM Q I I I I I I I I I + 1 7 u υ u o o o u u W »XJ O 0 0 0000 o CMioun m in m p nfio ρΗττγη μ · · <3 · ^ j · p cn π \ ø OCM Q I I I I I I I I I + 1 7 u υ u o o o u u W »XJ O 0 0 0000 o CMion m in m p n

Oioooo co co oo a> mOioooo co co oo a> m

• pH pH rH pH pH pH pH pH• pH pH rH pH pH pH pH pH

Qj III I I I I IQj III I I I I I

E pH «Τ CN T "O' P CO CME pH «Τ CN T„ O 'P CO CM

w cn co co cooooor-- mw cn co co cooooor-- m

årHrHrH pHpHpHpH pHyearHrH pHpHpHpH pH

PP

P E c S KBP E c S KB

>1 0 0) o o o> 1 0 0) o o o

COH^CU) P P P rH rH pH rH 0] 10 rHCOH ^ CU) P P P rH rH pH rH 0] 10 rH

OOOOOUOOOO L> ω ηβχχχχβχεηε-· b r*i <0 r cn s o 01 0) p Σ.OOOOOUOOOO L> ω ηβχχχχβχεηε- · b r * i <0 r cn s o 01 0) p Σ.

0) P0) P

EP O 0 0 o« o o o o po o o o m p in O OOCMO’O' «· O' O' r- m ». p •Η'-' *> 1. *» ·* CN ·· * t - Γθ f*·* o miOiOrTPOPPPP rr 0)0 + + I + + I I + I I Π ΡΙΜΟ oi r~i P g w *2ι υ υ υ ο υ u o u υ <0 oooooooooo o η· io in -ctt oio m o *r c- ooEP O 0 0 o «o o o o po o o o m p in O OOCMO'O '« · O' O 'r- m ». p • Η'- '*> 1. * »· * CN ·· * t - Γθ f * · * o miOiOrTPOPPPP rr 0) 0 + + I + + II + II Π ΡΙΜΟ oi r ~ i P gw * 2ι υ υ υ ο υ uou υ <0 oooooooooo o η · io in -ctt oio mo * r c- oo

Q & p O O O ro cm O o <N O OQ & p O O O ro cm O o <N O O

H PPPPPPPPPP pH PPPPPPPPPP p

CO I I I I I I I I 1 I ICO I I I I I I I I 1 I I

ιητίΡΙΝΟΟιηΗίΓ-ίΝιΟ Γ-ιητίΡΙΝΟΟιηΗίΓ-ίΝιΟ Γ-

ΡΟ oo CM CM O O CM O OCM oo CM CM O O CM O O

P P PP PP P p p p *—t Ό \ N SS p. p P pppppjjpijjj 7jP P PP PP P p p p * —t Ό \ N SS p. P P pppppjjpijjj 7j

i § j3£gj3gj3 3!aJ3£S S 3 5 S Si § j3 £ gj3gj3 3! aJ3 £ S S 3 5 S S

©o i ΐχ « H ji liS ¢5 « "5 -¾ S© o i ΐχ «H ji liS ¢ 5« "5 -¾ S

"p G P TZ* U <D CuuS U O S U S) & o nhl O-HO) >1 Oi O l5£ |J i? o [g S S ΰ Si"p G P TZ * U <D CuuS U O S U S) & o nhl O-HO)> 1 Oi O l5 £ | J i? o [g S S ΰ Si

oco jBp.pt> 22 22-5 22-Soco jBp.pt> 22 22-5 22-S

II it 8 It I Is. A s k |t ItII it 8 It I Is. A s k | t It

Qdl H[) hhO1 h a øg1 g ^Qdl H [) hhO1 h a øg1 g ^

XX

oisland

B x XI BB XI XX XW x XI BB XI XX X

0> 0000)00 00)00 o p i i i Λ il ι ι χ i i i >< οιαίφο,ρρρ—α,ωα) ai0> 0000) 00 00) 00 o p i i i Λ il ι ι χ i i i> <οιαίφο, ρρρ — α, ωα) ai

W XXXI cn >1 > P I X X XW XXXI cn> 1> P I X X X

B Λ CUB X E-* ¢-) 3 Μ X CU CU XB Λ CUB X E- * ¢ -) 3 Μ X CU CU X

I 1 II II ICQOOI I II 1 II II ICQOOI I I

N N NN NN N—XIN N N , ρ >—1N N NN NN N — XIN N N, ρ> —1

0) P P P P P P .—I i—) I i—I p p rH0) P P P P P P. — I i—) I i — I p p rH

P B >1 >1 >1 >1 >H >1 >, >, O >. >, >1 CP B> 1> 1> 1> 1> H> 1>,>, O>. >,> 1 C

co xnnnnnnnpnn x nco xnnnnnnnpnn x n

» PcacccccPcc p X»PcacccccPcc p X

0) O) 0)0) 0)0) OJ (D-HOIO) 0) , ε b cqo mm m χ z x ra ε y I lo p o I χ ??0) O) 0) 0) 0) 0) OJ (D-HOIO) 0), ε b cqo mm m χ z x ra ε y I lo p o I χ ??

° o S° o S

CXOhhhhhhhhm O·CXOhhhhhhhhm O ·

H PppHHHHHHHHH M »p i—IH PppHHHHHHHHH M »p i — I

E <0 >. H H HH HH Η Η Η Η H >i>,iPE <0>. H H HH HH Η Η Η Η H> i>, iP

P η υ ω x X x x x x x x x x x NE>, o GPU) <0 p ai o o e-1 0) CQ Eti £h c 1 i a 11 11 CO CHfOM-inor-COcnOP CM , x P P p 11 SH cnP η υ ω x X x x x x x x x x x NE>, o GPU) <0 p ai o o e-1 0) CQ Eti £ h c 1 i a 11 11 CO CHfOM-inor-COcnOP CM, x P P p 11 SH cn

ω O Oω O O

N fri Eh 21 DK 174386 B1 På analog måde fremstilles [cis-endo]-imino-a~ -carboxylsyreesterne fra tabel I og underkastes en racematspaltning. i denne tabel er deres optisk aktive krystallisationspartnere, opløsningsmidler, udbytter og 5 egenskaber af saltene og af slutprodukterne i form af ester-hydrochlorider eller tosylater anført.N free Eh 21 GB 174386 B1 In an analogous manner, the [cis-endo] -imino-α-carboxylic acid esters are prepared from Table I and subjected to a racemate cleavage. In this table their optically active crystallization partners, solvents, yields and properties of the salts and of the end products in the form of ester hydrochlorides or tosylates are listed.

Forklaringer til tabel IExplanations for Table I

10 H10 H

(XI) _ og spejlbilleder(XI) _ and mirror images

'COOR'COOR

-· 1 Η H- · 1 Η H

1515

HH

Un) og spejlbillederUn) and mirror images

'-COOR'-COOR

Η HΗ H

25 H25 H

/v t t t ^ Jjt og spejlbilleder/ v t t t ^ Jjt and mirror images

0/.....COOR0 / ..... COOR

il \il \

Η HΗ H

3030

Ud fra esterne kan de frie iminocarboxylsyrer fremstilles ved forsæbning eller hydrogenolyse.From the esters, the free iminocarboxylic acids can be prepared by saponification or hydrogenolysis.

35 DK 174386 B1 2235 DK 174386 B1 22

Eksempel 13 N-(lS-Carbethoxy-3-phenyl-propyl)-S-alanyl-2-cis,endo--azabicyclo[3♦3.0]octan-3S-carboxylsyre_ (A) N- (lS-Carbethoxy-3-phenyl-propyl)-S-alanyl- 5 -cis,endo-2-azabicyclo[3.3.0]octan-3S-carboxy1- _syrebenzylester_ 14 g af det ifølge eksempel 1E fremstillede benzyl-esterhydrochlorid overføres ved udrystning af den vandige alkaliske opløsning med diethylether i den frie ester, 10 som efter afdestillering af etheren bringes til at reagere med 6,7 g HOBt, 13,8 g N-(lS-carbethoxy-3--phenylpropyl)-S-alanin og 10,2 g dicyclohexylcarbodiimid i 200 ml dimethylformamid. Efter 3 timers omrøring ved stuetemperatur skilles der fra det udfældede dicyclohexyl-15 urinstof ved sugning, der koncentreres og optages i 1 liter ethylacetat, derefter udrystes der med 3 x 500 ml 5%'s NaHC03-opløsning. Den organiske fase koncentreres.Example 13 N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl-2-cis, endo-azabicyclo [3 ♦ 3.0] octane-3S-carboxylic acid (A) N- (1S-Carbethoxy-3 phenyl-propyl) -S-alanyl-5-cis, endo-2-azabicyclo [3.3.0] octane-3S-carboxylic acid benzyl ester 14 g of the benzyl ester hydrochloride prepared according to Example 1E is transferred by shaking the aqueous alkaline solution with diethyl ether in the free ester, which, after distilling off the ether, is reacted with 6.7 g of HOBt, 13.8 g of N- (1S-carbethoxy-3-phenylpropyl) -S-alanine and 10.2 g of dicyclohexylcarbodiimide in 200 ml of dimethylformamide. After stirring at room temperature for 3 hours, the precipitated dicyclohexyl-urea is separated by suction, concentrated and taken up in 1 liter of ethyl acetate, then shaken with 3 x 500 ml of 5% NaHCO3 solution. The organic phase is concentrated.

Der fås 22,4 g (90%) produkt i form af olie.22.4 g (90%) of product is obtained in the form of oil.

20 ^H-NMR af S,S,S-forbindelsen, karakteristiske signaler: 1,20 (d,3H), 1,27 (t,2H), 4,17 (q,3H), 5,13 (s,2H), 7,18 (s,5H), 7,32 <s,5H) (CDC13)20 H NMR of the S, S, S compound, characteristic signals: 1.20 (d, 3H), 1.27 (t, 2H), 4.17 (q, 3H), 5.13 (s, 2H), 7.18 (s, 5H), 7.32 (s, 5H) (CDCl3)

Analyse: C Η NAnalysis: C Η N

25 C3QH38N205 beregnet 71,1 7,56 5,53 fundet 70,8 7,8 5,7 (B) N- (lS-Carbethoxy-3-phenyl-propyl)-S-alanyl--cis,endo-2-azabicyclo[3.3.0]octan-3-S- 30 _ -carboxylsyre_ 8,0 g af S,S,S-benzylesteren fra eksempel E opløses i 100 ml ethanol og afbenzyleres hydrogenolytisk under tilsætning af 0,5 g 10%’s Pd/C ved normaltryk. Denne reaktion kan også foretages under tryk med en samtidig 35 forkortelse af reaktionstiden. Efter optagelse af den beregnede mængde hydrogen filtreres der fra katalysatoren, 23 DK 174386 B1 og der koncentreres i vakuum. Zwitterionen udkrystalliserer i næsten kvantitativt udbytte fra ether. Smeltepunkt: 110-112°C (sønderdeling).Calcd. 71.1 7.56 5.53 Found 70.8 7.8 5.7 (B) N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl - cis, endo-2- azabicyclo [3.3.0] octane-3-S-30-carboxylic acid 8.0 g of the S, S, S-benzyl ester of Example E is dissolved in 100 ml of ethanol and debenzylated hydrogenolytically with the addition of 0.5 g of 10% Pd / C at normal pressure. This reaction can also be carried out under pressure with a simultaneous shortening of the reaction time. After taking up the calculated amount of hydrogen, the catalyst is filtered off and concentrated in vacuo. The zwitterion crystallizes in almost quantitative yield from ether. Melting point: 110-112 ° C (dec.).

Ved tilsætning af en ækvivalent mængde saltsyre 5 kan der fås et hydrochlorid (sønderdeling fra 120°C).By adding an equivalent amount of hydrochloric acid 5, a hydrochloride (decomposition from 120 ° C) can be obtained.

Analyse: C Η NAnalysis: C Η N

^23H32N2^5 bere9net 66,3 7,7 6,73 fundet 66,1 7,8 6,6 10 De opnåede ^H-NMR- og massespektre er i overens stemmelse med den angivne struktur.Calcd. 66.3 7.7 6.73 Found 66.1 7.8 6.6 The obtained 1 H-NMR and mass spectra are consistent with the structure indicated.

[a]D = +15,6°C (c = 1, methanol).[α] D = + 15.6 ° C (c = 1, methanol).

Eksempel 14 15 N-(lS-Carbethoxy-2-benzoyl-ethyl)-O-ethyl-S-tyrosyl--cis,endo-2-azabicyclo[3.3.0]-octan-3S-carboxylsyre (A) N-(lS-Carbethoxy-3-benzoyl-ethyl)-0-ethyl- _-S-tyrosyl-benzyles ter___________ 24 g benzoylacrylsyre-ethylester i 100 ml ethanol 20 omsættes med 30 g O-ethyl-S-tyrosin-benzylester i nærværelse af 0,5 ml triethylamin, og efter koncentrering af opløsningen og digerering af remanensen med diethylether/petroleums- ether i forholdet 1:1 og tørring i vakuum fås 42 g R, S,S-forbindelse. Diastereomeradskillelse ved chromato-25 grafi på silicagel i systemet eddikeester/cyclohexan i forholdet 1:3.Example 14 N- (1S-Carbethoxy-2-benzoyl-ethyl) -O-ethyl-5-tyrosyl - cis, endo-2-azabicyclo [3.3.0] -octane-3S-carboxylic acid (A) N- ( (1S-Carbethoxy-3-benzoyl-ethyl) -O-ethyl-_-S-tyrosyl-benzyls. 24 g of benzoylacrylic acid ethyl ester in 100 ml of ethanol is reacted with 30 g of O-ethyl-S-tyrosine-benzyl ester in the presence of 0 , 5 ml of triethylamine, and after concentrating the solution and digesting the residue with diethyl ether / petroleum ether in a 1: 1 ratio and drying in vacuo, 42 g of R, S, S compound are obtained. Diastereomer separation by chromatography on silica gel in the vinegar ester / cyclohexane 1: 3 ratio.

Udbytte: 17 g af S,S-forbindeIsen.Yield: 17 g of S, S compound.

(B) N-(lS-Carbethoxy-3-benzoy1-ethyl)-Q-ethyl-S-tyrosin 30 17 g af den forbindelse, der fås ifølge (A), hydrogeneres i 800 ml eddikesyre med 4 g Pd/C (10%'s) ved 10.000 kPa og stuetemperatur. Udbytte efter chromatografi på silicagel i en blanding af ethylacetat og cyclohexan i forholdet 1:3 som opløsningsmiddel og tørring af ind-35 dampningsremanensen: 12 g tyndtlags-chromatografisk næsten ensartet titelforbindelse. Smp, 205-213°C.(B) N- (1S-Carbethoxy-3-benzoyl-ethyl) -Q-ethyl-S-tyrosine 30 g of the compound obtained according to (A) is hydrogenated in 800 ml of acetic acid with 4 g of Pd / C ( 10%) at 10,000 kPa and room temperature. Yield after chromatography on silica gel in a mixture of ethyl acetate and cyclohexane in the ratio of 1: 3 as solvent and drying the evaporation residue: 12 g of thin layer chromatographic almost uniform title compound. Mp, 205-213 ° C.

24 DK 174386 B124 DK 174386 B1

Analyse: C23H29N05 (399,5) beregnet C 69,15 H 7,31 N 3,50 fundet C 69,5 H7,4 N3,3 (C) N-(lS-Carbethoxy-3-benzoyl-ethyl)-O-ethyl-S-5 -tyrosy1-c is-endo-2-azabicyclo[3.3.0]octan- ___-3S-carboxylsyre_Analysis: C 23 H 29 NO 5 (399.5) Calcd C 69.15 H 7.31 N 3.50 Found C 69.5 H7.4 N3.3 (C) N- (1S-Carbethoxy-3-benzoyl-ethyl) -O -ethyl-S-5-thyroxy-cis-endo-2-azabicyclo [3.3.0] octane-___- 3S-carboxylic acid

Analogt raed eksempel 13A omsættes 8 g af den frie benzylester, som fås ifølge eksempel 1E og efter ud-rystning med diethylether fra basisk opløsning, med 8 g 10 af den ifølge eksempel 14B opnåede forbindelse ved hjælp af 4,4 g dicyclohexylcarbodiimid i nærværelse af 2,7 g 1-hydroxybenzotriazol, og herved fås 14,3 g olieagtig benzylester som mellemprodukt.By analogy to Example 13A, 8 g of the free benzyl ester obtained according to Example 1E and after shaking with diethyl ether from basic solution are reacted with 8 g 10 of the compound of Example 14B using 4.4 g of dicyclohexylcarbodiimide in the presence of 2.7 g of 1-hydroxybenzotriazole to give 14.3 g of oily benzyl ester as an intermediate.

og massespektret er i overensstemmelse med 15 den angivne struktur.and the mass spectrum is in accordance with the structure indicated.

Benzylesteren hydrogeneres katalytisk i 50 ml ethanol under normaltryk på Pd/C. Efter frafiltrering af katalysatoren og afdestillering af opløsningsmidlet bliver der en fast remanens tilbage, som digereres med 20 en blanding af diethylether og petroleumsether og tørres. Udbytte: 11,2 g.The benzyl ester is catalytically hydrogenated in 50 ml of ethanol under normal pressure on Pd / C. After filtering off the catalyst and distilling off the solvent, a solid residue is left, which is digested with a mixture of diethyl ether and petroleum ether and dried. Yield: 11.2 g.

Eksempel 15 N-(lS-Carbethoxy-3-phenyl-propyl)-O-methyl-S-tyrosyl- 25 -cis,endo-2-azabicyclo[3.3,0]octan-3S-carboxylsyre_Example 15 N- (1S-Carbethoxy-3-phenyl-propyl) -O-methyl-5-tyrosyl-cis, endo-2-azabicyclo [3.3.0] octane-3S-carboxylic acid

Man arbejder som beskrevet i eksempel 14, men i det med (A) analoge trin anvendes O-methyl-S-tyrosin- -benzylester, og der fås titelforbindelsen, hvis ^H-NMR- “spektrum er i overensstemmelse med den angivne struktur.One works as described in Example 14, but in the (A) analog step, O-methyl-S-tyrosine-benzyl ester is used and the title compound is obtained if 1 H-NMR spectrum is consistent with the structure indicated.

30 1H-NMR (CDC13)x 1,2-3,0 (m,15H); 1,27 (t,3H),* 1,4 (t,3H),' 3,0-4,3 (m,4H); 3,8-4,2 (m,4H),* 6,5-7,1 (2d, 4H) ,* 7,3 (s,5H) .1 H-NMR (CDCl 3) x 1.2-3.0 (m, 15H); 1.27 (t, 3H), * 1.4 (t, 3H), 3.0-4.3 (m, 4H); 3.8-4.2 (m, 4H), * 6.5-7.1 (2d, 4H), * 7.3 (s, 5H).

35 25 DK 174386 B135 25 DK 174386 B1

Eksempel 16 N-(lS-Carbethoxy-3-phenyl-propyl)-S-alanyl-spiro[4.5]- -2-azadecan-3S-carboxylsyre_________ (A) 1-(Diethoxyethyl)-cyclohexancarbonitril 5 Til 312 ml (0,5 mol) af en 15%'s opløsning af n-butyllithium i hexan dryppes ved -10°C under beskyttelsesgas 51,7 ml (0,5 mol) vandfri diethylamin.Example 16 N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl-spiro [4.5] -2-azadecane-3S-carboxylic acid _________ (A) 1- (Diethoxyethyl) -cyclohexanecarbonitrile 5 To 312 ml (0, 5 mol) of a 15% solution of n-butyllithium in hexane is dropped at -10 ° C under protective gas 51.7 ml (0.5 mol) of anhydrous diethylamine.

Der omrøres i 20 minutter, og derpå afkøles til -70°C.Stir for 20 minutes and then cool to -70 ° C.

I løbet af 30 minutter tildryppes 54,6 g cyclohexancarbo-10 nitril, efter yderligere 30 minutter tilsættes indenfor 1 time 98,5 g bromacetaldehyd-diethylacetal, og blandingen henstilles i 24 timer ved lav temperatur. Der opvarmes til stuetemperatur, der tilsættes 100 g is, og der ekstra-heres tu gange med -500 ml ethylaceLaL , deri organiske 15 fase tørres over natriumsulfat, der koncentreres i vakuum, og remanensen underkastes vakuumdestillation.Over 30 minutes, 54.6 g of cyclohexane carbonitrile are dropped, after another 30 minutes, 98.5 g of bromoacetaldehyde diethyl acetal are added within 1 hour and the mixture is allowed to stand for 24 hours at low temperature. Heat to room temperature, add 100 g of ice and extract twice with -500 ml of ethyl acetate, dry in organic phase over sodium sulfate, which is concentrated in vacuo and subject to vacuum distillation.

Udbytte: 90 g (ca. 80% af teorien), kp. 78-79°C ved 1070 kPa.Yield: 90 g (about 80% of theory), b.p. 78-79 ° C at 1070 kPa.

20 (B) 1-Aminoethyl-l-(diethyloxyethyl)-cyclohexan 90 g diethyloxyethyl-cyclohexancarbonitril opløses i 1 liter ethanol, og der tilsættes 60 g natrium. Efter opløsning af metallet tilsættes 100 ml vand, og opløsningsmidlet fjernes i stor udstrækning i vakuum.(B) 1-Aminoethyl-1- (diethyloxyethyl) -cyclohexane 90 g of diethyloxyethyl-cyclohexanecarbonitrile are dissolved in 1 liter of ethanol and 60 g of sodium are added. After dissolving the metal, 100 ml of water is added and the solvent is extensively removed in vacuo.

25 Der sættes 300 ml vand til remanensen, og der ekstra- heres med 3 x 200 ml ether. Etherfasen tørres over natriumsulfat, koncentreres og destilleres i vakuum.25 ml of water are added to the residue and extracted with 3 x 200 ml of ether. The ether phase is dried over sodium sulfate, concentrated and distilled in vacuo.

Udbytte: 83 g (ca. 90% af teorien), kp. 69-72°C ved 1070 kPa.Yield: 83 g (about 90% of theory), b.p. 69-72 ° C at 1070 kPa.

30 (C) Spiro[4.5]-2-azadecan-3-carbonitril 80,2 g aminomethyl-diethyloxyethyl-cyclohexan indrøres under beskyttelsesgas (N2 eller Ar) i en blanding af 300 ml ethanol og 300 ml 1 N saltsyre i ca. 1 time.(C) Spiro [4.5] -2-azadecan-3-carbonitrile 80.2 g of aminomethyl diethylloxyethyl-cyclohexane is stirred under protective gas (N2 or Ar) in a mixture of 300 ml of ethanol and 300 ml of 1N hydrochloric acid 1 hour.

35 Efter fuldstændig spaltning af udgangsproduktet afkøles35 After complete decomposition of the starting product, cool

til 0°C, og opløsningen bringes ved tilsætning af 2 Nto 0 ° C and the solution is brought by the addition of 2 N

26 DK 174386 B1 natriumhydroxidopløsning hurtigt på pH 5. Man tilsætter straks 300 ml iseddike (pH ca. 3), afkøler til -10°C og tilsætter 17,5 g natriumcyanid. Reaktionsbeholderen lukkes og henstilles i ca. 5 timer ved stuetemperatur.26 DK 174386 B1 sodium hydroxide solution rapidly at pH 5. Immediately add 300 ml of glacial acetic acid (pH approx. 3), cool to -10 ° C and add 17.5 g of sodium cyanide. The reaction vessel is closed and left for approx. 5 hours at room temperature.

5 Ved hjælp af tyndtlagschromatografi (system ethylacetat/ petroleumsether i forholdet 2:1) kontrolleres det, om omsætningen er fuldstændig (Schiff'sk base Rf - 0,6-0,7; aminonitril = 0,28) og man inddamper reaktionsopløsningen til tørhed. Det rå aminonitril videreforarbejdes 10 straks ifølge eksempel 16D eller E.5 Thin layer chromatography (2: 1 ethyl acetate / petroleum ether system) checks to see if the reaction is complete (Schiff's base Rf - 0.6-0.7; aminonitrile = 0.28) and evaporates the reaction solution to dryness . The crude aminonitrile is further processed immediately according to Example 16D or E.

(D) Spiro[4,5]-2-azadecan-3-carboxylsyre(D) Spiro [4,5] -2-azadecane-3-carboxylic acid

Til halvdelen af det i eksempel 16C opnåede aminonitril sættes 250 ml 4N saltsyre, og der opvarmes 15 i 4 timer under tilbagesvaling. Spor af udsivende blåsyre uskadeliggøres på egnet måde (udfrysning, absorption i basisk jern-(II)-saltopløsning). Opløsningen neutraliseres, bringes til tørhed og ekstraheres gentagne gange med n-butanol. Afdampningsremanensen fra 20 den organiske fase a) krystalliseres til indvinding af hydrochloridet fra chloroform-diisopropylether, og om nødvendigt omkrystalliseres én gang til fra en blanding med ethanol, eller 25 b) renses ved udrøring med ionbytter, f.eks.To half of the aminonitrile obtained in Example 16C is added 250 ml of 4N hydrochloric acid and heated for 15 hours under reflux. Traces of leaking hydrochloric acid are rendered harmless in a suitable manner (freezing, absorption in basic iron (II) salt solution). The solution is neutralized, brought to dryness and extracted repeatedly with n-butanol. The evaporation residue from organic phase a) is crystallized to recover the hydrochloride from chloroform-diisopropyl ether and, if necessary, recrystallized from a mixture with ethanol, or b) purified by stirring with ion exchange, e.g.

IR 45 (OH-form) (1\mberlite ®") i en vandig opløsning, og efter fjernelse af vandet udkrystalliseres zwitter-ionen fra en blanding af ethanol og ether.IR 45 (OH form) (1 µmberlite®) in an aqueous solution, and after removal of the water, the zwitter ion is crystallized from a mixture of ethanol and ether.

Udbytte ifølge a): 31-32 g (82%) 30 Smp. 205°C (sønderdeling), hydrochlorid (E) Spiro[4.5]-2-aza-decan-3-carboxylsyrebenzylester- _hydrochlorid________Yield according to a): 31-32 g (82%). 205 ° C (decomposition), hydrochloride (E) Spiro [4.5] -2-aza-decane-3-carboxylic acid benzyl ester hydrochloride

Halvdelen af det i eksempel 16c opnåede aminosyre-35 nitril optages i 70 ml benzylalkohol. Ved stuetemperatur ledes i 5 minutter en langsom HCl-gasstrøm gennem opløsningen, 27 DK 174386 B1 som holdes i 2 - 3 timer ved stuetemperatur, der koncentreres godt i vakuum, der tilsættes vandig natriumbicarbonatopløsning, indtil pH 8,5 nås, og benzylesteren ekstraheres i ethylacetat. Den organiske 5 fase tørres, og der tilsættes en ækvivalent mængde etherisk saltsyre og koncentreres. Remanensen udkrystalliserer fra diisopropylether og kan omkrystalliseres fra methylen-chlorid/diisopropylether.Half of the amino acid nitrile obtained in Example 16c is taken up in 70 ml of benzyl alcohol. At room temperature, for 5 minutes, a slow HCl gas stream is passed through the solution, maintained for 2 - 3 hours at room temperature, which is well concentrated in vacuo, aqueous sodium bicarbonate solution is added until pH 8.5 is reached and the benzyl ester is extracted in ethyl acetate. The organic phase is dried and an equivalent amount of ethereal hydrochloric acid is added and concentrated. The residue crystallizes from diisopropyl ether and can be recrystallized from methylene chloride / diisopropyl ether.

Udbytte: 43 g (ca. 80%) O Smp. 145°C (sønderdeling).Yield: 43 g (about 80%). 145 ° C (dec.).

(F) Spiro[4.5]-2-azadecan-3S-carboxylsyrebenzyl- _ester-hydrochlor id_______(F) Spiro [4.5] -2-azadecane-3S-carboxylic acid benzyl ester hydrochloride

Det racemiskc hydrochlcrid, som fås ifølge eksempel 15 16E, underkastes analogt med eksemplerne ID og E en racemat spaltning .The racemic hydrochloride obtained in Example 15 16E is subjected to a racemate cleavage analogously to Examples ID and E.

(G) N- (lS-Carbethoxy-3-phenyl-propyl)-S-alanyl--spiro[4.5]-2-azanonan-3S-carboxylsyre-benzyl- 20 _ ester _ 15,6 g spiro[4.5]-2-azanonan-3S-carboxylsyre-benzylester-hydrochlorid, 6,7 g 1-hydroxybenzotriazol og 13,8 g (S,S)-N-(l-carbethoxy-3-phenyl-propyl)-alanin opløses i 200 ml DMF og bringes til at reagere med 25 10,2 g dicyclohexylcarbodiimid i løbet af natten.(G) N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl-spiro [4.5] -2-azanonan-3S-carboxylic acid benzyl ester - 15.6 g spiro [4.5] - 2-Azanonan-3S-carboxylic acid benzyl ester hydrochloride, 6.7 g of 1-hydroxybenzotriazole and 13.8 g of (S, S) -N- (1-carbethoxy-3-phenyl-propyl) -alanine are dissolved in 200 ml of DMF and reacted with 10.2 g of dicyclohexylcarbodiimide overnight.

Tilsætning af tertiære baser, f.eks. 6,4 ml N-ethylmorpho-lin, forhøjer kun udbyttet uvæsentligt. Der filtreres fra det udfældede DC-urinstof, filtratet koncentreres i vakuum, der optages i ethylacetat, udrystes med 30 vandig natriumbicarbonatopløsning, den vandige fase tørres over fast natriumsulfat, og der koncentreres på ny. ^H-NMR-spektret (i CDCl^) bekræfter strukturen.Addition of tertiary bases, e.g. 6.4 ml of N-ethylmorpholine, only slightly increases the yield. Filter from the precipitated DC urea, concentrate the filtrate in vacuo, taken up in ethyl acetate, shake with 30 aqueous sodium bicarbonate solution, dry the aqueous phase over solid sodium sulfate, and re-concentrate. 1 H-NMR spectrum (in CDCl3) confirms the structure.

35 28 DK 174386 B1 (H) N- (lS-Carbethoxy-3-phenyl-propyl)-S-alanyl- _-spiro[4.5]-2-azanonan-3S-carboxylsyre_28 (174) B1 (H) N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl-spiro [4.5] -2-azanonan-3S-carboxylic acid

Den i eksempel 16G opnåede benzylester optages i 200 ml methanol og afbenzyleres hydrogenolytisk med 5 1 g Pd/C (10% Pd). Efter afsluttet hydrogenoptagelse filtreres, og der koncentreres i vakuum. Under tilsætning af pentan kan der i vakuum fås et fast, hygroskopisk skum af det zwitterioniske dipeptidderivat.The benzyl ester obtained in Example 16G is taken up in 200 ml of methanol and hydrogenolytically debenzylated with 5 1 g of Pd / C (10% Pd). After hydrogen uptake is completed, filter and concentrate in vacuo. With the addition of pentane, a solid hygroscopic foam of the zwitterionic dipeptide derivative can be obtained in vacuo.

[ajp1 = 38,3° (c = 1, methanol) 10[α] D = 38.3 ° (c = 1, methanol) 10

Eksempel 17 N-(lS-Carbethoxy-3-phenyl-prppyl)-S-alanyl-cis,endo-2,3,3a, 4,5,7a-hexahydro [ IH] indol-2S-carboxyIsyre_ ....Example 17 N- (1S-Carbethoxy-3-phenylpropyl) -S-alanyl-cis, endo-2,3,3a, 4,5,7a-hexahydro [1H] indole-2S-carboxylic acid ...

(A) cis-2,3,3a,4,5,7a-Hexahydro[lH]indol-2S- 15 _-carboxylsyremethylester-hydrochlorid_(A) cis-2,3,3a, 4,5,7a-Hexahydro [1H] indole-2S-15-carboxylic acid methyl ester hydrochloride

Racemisk cis-2,3,3a,4,5,7a-hexahydro[IH]indol--2-carboxylsyremethylester-hydrochlorid (kan opnås analogt med den i DE-offentliggørelsesskrift nr. 32 10 496 beskrevne fremgangsmåde) underkastes analogt med eksemp-20 lerne ID og E en racematspaltning.Racemic cis-2,3,3a, 4,5,7a-hexahydro [1H] indole-2-carboxylic acid methyl ester hydrochloride (obtainable by analogy to the process described in DE Publication No. 3210496) is subjected, by way of example, to 20 ID and E a racemate cleavage.

[a]D = +68,4° (c = 1, H20).[α] D = + 68.4 ° (c = 1, H2 O).

(B) N-(lS-Carbethoxy-3-phenyl-propyl)-S-alanyl--cis,endo-2,3,3a,4,5,7a-hexahydro[IH]indol- 25 __ -2S-carboxylsyre-hydrochlorid_(B) N- (1S-Carbethoxy-3-phenyl-propyl) -S-alanyl-cis, endo-2,3,3a, 4,5,7a-hexahydro [1H] indole-2 -2-carboxylic acid -hydrochlorid_

Man får titelforbindelsen analogt med den i eksemplerne 13A og B beskrevne fremgangsmåde.The title compound is obtained analogously to the process described in Examples 13A and B.

1H-NMR-data 0,9 - 3,0 (m, 17 H)J 3,4 - 4,9 (m, 6 H)) 30 5,2 - 6,0 (m, 2 H); 7,2 (s, 5 H).1 H NMR data 0.9 - 3.0 (m, 17H) J 3.4 - 4.9 (m, 6H)) 5.2 - 6.0 (m, 2H); 7.2 (s, 5H).

3535

Claims (12)

29 DK 174386 B129 DK 174386 B1 1. Fremgangsmåde til adskillelse af racemiske blandinger af bicycliske imino-a-carboxylsyreestere i komponenterne med formlen la og Ib 5 B2 C C B2 -V7 ,„c'yJ ΑΧ ΧΛ, 1 i Η H C la) C Ib) 15 i hvilke R står for en aliphatisk gruppe med 1-6 C-atomer, en alicyclisk gruppe med 4-10 C-atomer, 20 en aromatisk gruppe med 6-12 C-atomer, eller en arallphatisk gruppe med 7-15 C-atomer, som eventuelt kan være substitueret med N02, a) A og B1 betyder hydrogen, og B og C danner tilsammen en kæde med formlen -(Cl^) - 25 med n = 3, 4, 5 eller 6 eller en kæde med formlen -(CH_) -CH=CH-(CH_) - med (p+q) =1, 2, z p 2 q 3 eller 4, eller 2 b) C og B betyder hydrogen, og A og danner tilsammen en kæde med formlen -(CH_) - 2 n 30 med n = 3, 4, 5 eller 6 eller en kæde med formlen “(CH ) -CH=CH-(CH~) - med (p+q) = 1, 2, 3 eller 4, 2 p 2 q eller c) A og C betyder hydrogen, og 1 2 B og B danner tilsammen en kæde med formlen — <CH_) - 2 m 35 med m = 4, 5, 6 eller 7, eller det tilsvarende hydrochlorid- eller tosylatsalt 30 DK 174386 B1 ved krystallisation af diastereomere salte, kendetegnet ved, at man til en racemisk blanding af forbindelser med formel la eller Ib sætter en N-acyleret, optisk aktiv R- eller S-aminocarboxylsyre, som indeholder en phenylkerne, 5 og hvis aminofunktion og eventuelt tilstedeværende, frie hydroxyfunktioner eventuelt er beskyttet, hvorefter de dannede salte omkrystalliseres fra et aprotisk organisk opløsningsmiddel eller en alkohol med op til 6 C-atomer, de udfældede, optisk ensartede diastereomere salte adskilles på i 10 og for sig kendt måde, og enantiomerene med formlen la eller Ib isoleres, eventuelt i form af deres hydrochlorid- eller tosylatsaltA process for separating racemic mixtures of bicyclic imino-α-carboxylic acid esters into the components of formula Ia and Ib 5 B2 CC B2 -V7, "c'yJ ΑΧ ΧΛ, 1 in Η HCl) C Ib) 15 wherein R is for an aliphatic group having 1-6 C atoms, an alicyclic group having 4-10 C atoms, an aromatic group having 6-12 C atoms, or an arallphatic group having 7-15 C atoms which may optionally be substituted by NO2, a) A and B1 are hydrogen, and B and C together form a chain of formula - (C1-6) with n = 3, 4, 5 or 6 or a chain of formula - (CH2) - CH = CH- (CH_) - with (p + q) = 1, 2, zp 2 q 3 or 4, or 2 b) C and B denote hydrogen and A and together form a chain of formula - (CH_) - 2 n 30 with n = 3, 4, 5 or 6 or a chain of the formula “(CH) -CH = CH- (CH ~) - with (p + q) = 1, 2, 3 or 4, 2 p 2 q or c) A and C represent hydrogen and 1 2 B and B together form a chain of formula - <CH 2) - 2 m 35 with m = 4, 5, 6 or 7, e or the corresponding hydrochloride or tosylate salt or crystallization of diastereomeric salts, characterized in that an N-acylated, optically active R- or S-aminocarboxylic acid containing a racemic mixture of compounds of formula Ia or Ib is added a phenyl core, 5 and whose amino function and optionally free hydroxy functions are optionally protected, whereby the formed salts are recrystallized from an aprotic organic solvent or an alcohol of up to 6 C atoms, the precipitated optically uniform diastereomeric salts are separated into 10 and known manner and the enantiomers of formula Ia or Ib are isolated, optionally in the form of their hydrochloride or tosylate salt 2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at der fremstilles forbindelser med formlen la 15 eller Ib, hvor a) !\ og B1 betyder hydrogen, og 2 B og C danner tilsammen en kæde med formlen -(CH2) -med n = 3, 4, 5 eller 6 eller en kæde med formlen -(CH2)p-CH=CH-(CH2)q- med (p+q) =1, 2, 3 eller 4, eller 20 b) C og B2 betyder hydrogen, og A og danner tilsammen én af de ovenstående, under a) definerede kæder.Process according to claim 1, characterized in that compounds of formula Ia 15 or Ib are prepared, wherein a) and B1 are hydrogen, and 2 B and C together form a chain of formula - (CH 2) - with n = 3, 4, 5 or 6 or a chain of formula - (CH2) p -CH = CH- (CH2) q- with (p + q) = 1, 2, 3 or 4, or b) C and B2 means hydrogen, and A and together form one of the chains defined under (a) above. 3. Fremgangsmåde ifølge krav 2, kendetegnet ved, at man udskiller saltene af racemiske estere med formlen 25 ia eller Ib, i hvilke de to brohoved-hydrogenatomer er i cis-konfiguration, og COOR-gruppen er i endo-stilling i forhold til det bicycliske ringsystem» på krystallinsk form.Process according to claim 2, characterized in that the salts of racemic esters of formula 25 ia or lb are separated in which the two bridgehead hydrogen atoms are in cis configuration and the COOR group is in an endo position with respect to it. bicyclic ring system »in crystalline form. 4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, kendetegnet ved, at der fremstilles 30 forbindelser med formel la og Ib, hvor R står for alkyl med 1-6 C-atomer, cycloalkyl med 4-8 C-atomer eller aralkyl med 7-13 C-atomer, som eventuelt kan være substitueret med NO2·Process according to any one of claims 1-3, characterized in that 30 compounds of formula Ia and Ib are prepared, wherein R is alkyl of 1-6 C atoms, cycloalkyl of 4-8 C atoms or aralkyl having 7-13 C atoms, which may be optionally substituted with NO2 · 5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-4, kendetegnet ved, at aminofunktionen i 35 de til saltdannelsen anvendte N-acylerede R- eller S-amino-carboxylsyrer er beskyttet med alkanoyl med 1-6 C-atomer, 31 DK 174386 B1 tert.butoxycarbonyl, benzyloxycarbonyl eller andre i peptidkemien gængse N^-beskyttelsesgrupper, og eventuelt tilstedeværende, frie OH-funktioner i de N-acylerede aminosyrer eventuelt er beskyttet med alkyl med 1-6 C-atomer, benzyl 5 eller andre i peptidkemien gængse OH-beskyttelsesgrupper.Process according to any one of claims 1-4, characterized in that the amino function of the N-acylated R or S-amino-carboxylic acids used for the salt formation is protected by alkanoyl having 1-6 C atoms. 174386 B1 tert-Butoxycarbonyl, benzyloxycarbonyl or other N-protecting groups present in the peptide chemistry, and any free OH functions present in the N-acylated amino acids optionally protected by alkyl of 1-6 C atoms, benzyl 5 or others in the peptide chemistry common OH protecting groups. 6. Bicycliske imino-Q'-carboxylsyreestere med formlen I 1a eller I 1b B2 C C B2 10 bA / \ /b1 Xx. x\ Λ Ή Η . Η i i Η H 15 (11 a) (I’b) kendetegnet ved, at de to brohoved-hydrocenatomer 20 er i cis-konfiguration, COOR-gruppen er- i endo-stilling i forhold til det bicycliske ringsystem, det i forhold til COOR-gruppen cr-stillede C-atom har R- eller S - konf igurat ion, A, B1, B2 og C har de i krav 2 angivne betydninger, og R har de i krav 4 angivne betydninger, samt disses hydrochio-25 rid- eller tosylatsalte.6. Bicyclic imino-Q'-carboxylic acid esters of formula I 1a or I 1b B2 C C B2 10 bA / \ / b1 Xx. x \ Λ Ή Η. 15 ii Η H 15 (11 a) (I'b) characterized in that the two bridgehead hydrocene atoms 20 are in cis configuration, the COOR group is in an endo position relative to the bicyclic ring system, relative to the The COOR group cr-positioned C atom has R or S configuration, A, B1, B2 and C have the meanings given in claim 2 and R has the meanings given in claim 4 and their hydrochloride - or tosylate salts. 7. Forbindelse ifølge krav 6 eller 7, k e n d e -tegnet ved, at det til COOR-gruppen α-stillede C-atom er i S-konfiguration.A compound according to claim 6 or 7, characterized in that the C atom assigned to the COOR group is α-configuration. 8. Cis,endo-2-azabicyclo[3.3.0]octan-3S-carboxyl -30 syreester, hvor R har den i krav 4 angivne betydning.8. Cis, endo-2-azabicyclo [3.3.0] octane-3S-carboxylic acid ester, wherein R is as defined in claim 4. 9. Cis,endo-2-azabicyclo[3.3.0]octan-3S-carboxyl-syrebenzylester.9. Cis, endo-2-azabicyclo [3.3.0] octane-3S-carboxylic acid benzyl ester. 10. Cis,endo-octanhydro[IH]indol-2S-carboxylsyreester, hvor R har den i krav 4 angivne betydning.Cis, endo-octane hydro [1H] indole-2S-carboxylic acid ester, wherein R is as defined in claim 4. 11. Cis,endo-octahydro[IH]indol-23-carboxylsyrebenzy1 - ester. 32 DK 174386 B111. Cis, endo-octahydro [1H] indole-23-carboxylic acid benzyl ester. 32 DK 174386 B1 12. Diastereomert salt af en forbindelse med formlen I'a eller I'b angivet i krav 6, kendetegnet ved, at det diastereomere salt er i form af en N-acyleret, optisk aktiv R- eller S-aminocarboxylsyre, som indeholder en phe-5 nylkerne, og som er beskyttet som angivet i krav 5.Diastereomeric salt of a compound of formula Ia or I'b as claimed in claim 6, characterized in that the diastereomeric salt is in the form of an N-acylated optically active R- or S-aminocarboxylic acid containing a phe The nilbars and which are protected as claimed in claim 5.
DK198400415A 1983-01-31 1984-01-30 Bicyclic imino-alpha-carboxylic acid esters, process for their preparation by separating racemic mixtures thereof, optionally in the form of their hydrochloride or tosylate salt, and diastereomeric salt in the form of a protected N-acylated, ...... DK174386B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19833303139 DE3303139A1 (en) 1983-01-31 1983-01-31 Process for the preparation of carboxyalkyldipeptides
DE19833303112 DE3303112A1 (en) 1983-01-31 1983-01-31 METHOD FOR RACEMATE SEPARATION OF OPTICALLY ACTIVE BICYCLIC IMINO (ALPHA) CARBONIC ACIDS
DE3303112 1983-01-31
DE3303139 1983-01-31

Publications (3)

Publication Number Publication Date
DK41584D0 DK41584D0 (en) 1984-01-30
DK41584A DK41584A (en) 1984-08-01
DK174386B1 true DK174386B1 (en) 2003-01-27

Family

ID=25807929

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198400415A DK174386B1 (en) 1983-01-31 1984-01-30 Bicyclic imino-alpha-carboxylic acid esters, process for their preparation by separating racemic mixtures thereof, optionally in the form of their hydrochloride or tosylate salt, and diastereomeric salt in the form of a protected N-acylated, ......

Country Status (17)

Country Link
EP (1) EP0115345B1 (en)
JP (1) JPH0788358B2 (en)
KR (1) KR910001438B1 (en)
AU (1) AU566589B2 (en)
CA (2) CA1283249C (en)
DE (1) DE3468415D1 (en)
DK (1) DK174386B1 (en)
ES (2) ES529272A0 (en)
FI (1) FI88153C (en)
GR (1) GR82650B (en)
HU (1) HU191120B (en)
IE (1) IE56654B1 (en)
IL (1) IL70830A (en)
MA (1) MA20020A1 (en)
NO (1) NO166641C (en)
NZ (1) NZ206980A (en)
PT (1) PT78036B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500713A (en) * 1982-09-23 1985-02-19 Usv Pharmaceutical Corporation Therapeutic dipeptides
DE3345355A1 (en) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt METHOD FOR RACEMATE CLEAVING BICYCLIC IMINO (ALPHA) CARBONIC ACID ESTERS
WO1986000896A1 (en) * 1984-07-30 1986-02-13 Schering Corporation NOVEL PROCESS FOR THE PREPARATION OF CIS, ENDOOCTAHYDROCYCLOPENTA ADb BDPYRROLE-2-CARBOXYLATE
HU192914B (en) * 1985-02-11 1987-07-28 Richter Gedeon Vegyeszet Process for producing new 3-/substituted amino/-5-phenyl-2/3h/-furanone derivatives and pharmaceutically acceptable salts
FR2620703B1 (en) * 1987-09-17 1991-10-04 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERHYDROINDOLE CARBOXYLIC ACID - 2 (2S, 3AS, 7AS). APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES
HU904967D0 (en) * 1988-04-22 1991-01-28 Hoechst Ag Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
US6407262B1 (en) 2001-11-21 2002-06-18 Brantford Chemicals Inc. Process for the preparation of Ramipril
WO2006059347A2 (en) * 2004-12-01 2006-06-08 Morepen Laboratories Limited Improved process for preparation of ramipril
ES2686298T3 (en) 2010-04-20 2018-10-17 Chiral Quest, Inc. Enantioselective procedure for cycloalkenyl substituted beta alanines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (en) * 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
IE52663B1 (en) * 1980-04-02 1988-01-20 Warner Lambert Co Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids
US4374847A (en) * 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids

Also Published As

Publication number Publication date
NZ206980A (en) 1988-05-30
HU191120B (en) 1987-01-28
MA20020A1 (en) 1984-10-01
PT78036B (en) 1986-05-30
EP0115345B1 (en) 1988-01-07
ES8500228A1 (en) 1984-10-01
GR82650B (en) 1985-02-07
CA1283249C (en) 1991-04-16
KR910001438B1 (en) 1991-03-07
IL70830A (en) 1988-02-29
FI840350A0 (en) 1984-01-27
DK41584A (en) 1984-08-01
AU2393384A (en) 1984-08-02
HUT34159A (en) 1985-02-28
NO840350L (en) 1984-08-01
IE840210L (en) 1984-07-31
DK41584D0 (en) 1984-01-30
FI840350A (en) 1984-08-01
AU566589B2 (en) 1987-10-22
NO166641B (en) 1991-05-13
JPH0517439A (en) 1993-01-26
PT78036A (en) 1984-02-01
ES529272A0 (en) 1984-10-01
EP0115345A1 (en) 1984-08-08
FI88153B (en) 1992-12-31
DE3468415D1 (en) 1988-02-11
IE56654B1 (en) 1991-10-23
ES531284A0 (en) 1984-12-01
FI88153C (en) 1993-04-13
CA1317067C (en) 1993-04-27
JPH0788358B2 (en) 1995-09-27
NO166641C (en) 1991-08-21
ES8501759A1 (en) 1984-12-01
IL70830A0 (en) 1984-04-30

Similar Documents

Publication Publication Date Title
US4822894A (en) Optically active bicyclic imino-alpha-carboxylic esters
DK171256B1 (en) Analogous Process for Preparation of Bicyclic Amino Acid Derivatives or Physiologically Acceptable Salts thereof
US4714708A (en) Derivatives of cis, endo-2-azabicyclo[5.3.0]decane-3-carboxylic acid, and their use for treating hypertension
KR920001771B1 (en) A process for preparing n-alkylated dipetides
KR910000255B1 (en) Process for preparing tricyclic aminoacids derivatives
KR910003185B1 (en) Processes for preparation of spirocyclic aminoacid derivatives
JPH0694443B2 (en) Amino acid derivative
KR910009935B1 (en) Method of resolving bicyclic imino-alpha-carboxylic acid ester racemates
JPS5929686A (en) Novel derivatives of 2-azabicyclo(2,2,2)octane- 3-carbonic acid and manufacture
DK174386B1 (en) Bicyclic imino-alpha-carboxylic acid esters, process for their preparation by separating racemic mixtures thereof, optionally in the form of their hydrochloride or tosylate salt, and diastereomeric salt in the form of a protected N-acylated, ......
JPH0583541B2 (en)
PH26415A (en) Derivatives of bicyclic aminocarboxylic acids and process for their preparation
KR20040078680A (en) Process for the preparation of high purity perindopril and intermediates useful in the synthesis
JPH05320119A (en) Trifluoromethane sulfonyloxycarboxylic acid derivative and preparation thereof
US5175306A (en) Process for the resolution of racemates of optically active bicyclic imino-α-carboxylic esters
DK171893B1 (en) Azabicyclooctene derivatives or physiologically acceptable salts thereof, their preparation and use, drugs and intermediates for the preparation of the azabicyclooctene derivatives
CA1332943C (en) Process for preparing perhydrothiazepine derivatives
HU215926B (en) Process for producing optically active norbornyl amine derivatives
NO171976B (en) OPTICALLY ACTIVE BICYCLIC IMINO-ALFA CARBOXYLIC ACID ESTERS ALSO ALSO
FR2561243A1 (en) SULFAMIDES ANTIHYPERTENSEURS
NO162382B (en) NEW BICYCLIC AMINO ACIDS.
DE3303139A1 (en) Process for the preparation of carboxyalkyldipeptides

Legal Events

Date Code Title Description
PUP Patent expired